chlorthalidone profile

Chlorthalidone is a thiazide diuretic medication used to treat high blood pressure and fluid retention. It works by blocking the reabsorption of sodium and chloride in the kidneys, leading to increased urine production. Chlorthalidone is typically taken once daily. It is available in oral tablet form. Side effects can include dizziness, headache, and low blood pressure. Chlorthalidone is a commonly prescribed medication, and studies are ongoing to further investigate its efficacy and safety.'

Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	2732
CHEMBL ID	1055
CHEBI ID	3654
SCHEMBL ID	26234
MeSH ID	M0004215

Synonym
CHEMBL1055
chlortalidonum
BRD-A26384407-001-05-3
DIVK1C_000731
KBIO1_000731
MLS000069531 ,
smr000058635
natriuran
renon
zambesil
chlorphthalidolone
chlorothalidone
g 33182
phthalamodine
saluretin
chlorthalidone
g-33182
chlortalidone
2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide
hygroton
hydro-long
isoren
benzenesulfonamide,3-dihydro-1-hydroxy-3-oxo-1h-isoindol-1-yl)-
chlorphthalidone
nsc69200
chlorthalidon
igroton
benzenesulfonamide, 2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)-
77-36-1
oksodolin (oxodolin)
nsc-69200
phthalamudine
oradil
SPECTRUM_000146
demi-regroton
BPBIO1_000487
hsdb 3035
benzenesulfonamide, 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1h-isoindol-1-yl)-
clortalidona [inn-spanish]
chlortalidonum [inn-latin]
einecs 201-022-5
brn 0312295
racemic chlorthalidone
thalitone
(+-)-hygroton
oxodoline
urolin
famolin
(+-)-chlorthalidone
oxodolin
nsc 69200
clortalidone [dcit]
2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1h-isoindol-1-yl)benzenesulfonamide
3-hydroxy-3-(4-chloro-3-sulfamylphenyl)phthalimidine
1-oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline
PRESTWICK_759
2-chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1h-isoindol-1-yl)benzenesulfonamide
3-(4'-chloro-3'-sulfamoylphenyl)-3-hydroxyphthalimidine
1-keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline
CHEBI:3654 ,
NCGC00016317-01
cas-77-36-1
BSPBIO_000441
PRESTWICK2_000351
SPECTRUM5_000743
BSPBIO_002017
2-chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1h-isoindol-1-yl)benzene-1-sulfonamide
bdbm25900
AB00051946
DB00310
chlortalidone (jan/inn)
D00272
thalitone (tn)
chlorthalidone (usp)
hygroton (tn)
IDI1_000731
NCGC00094616-02
NCGC00094616-01
KBIOSS_000626
KBIOGR_001574
KBIO2_005762
KBIO2_000626
KBIO3_001237
KBIO2_003194
SPBIO_002362
SPECTRUM2_000099
PRESTWICK0_000351
SPBIO_000058
PRESTWICK1_000351
SPECTRUM4_000957
SPECTRUM3_000349
NINDS_000731
SPECTRUM1500187
PRESTWICK3_000351
NCGC00094616-04
NCGC00094616-03
HMS2091E12
AC-11367
HMS502E13
HMS1569G03
HMS1920M09
2-chloro-5-(1-hydroxy-3-oxo-2h-isoindol-1-yl)benzenesulfonamide
STK686335
A839067
2-chloro-5-[(1s)-1-hydroxy-3-oxo-isoindolin-1-yl]benzenesulfonamide;chlorthalidone
AKOS005599810
HMS3259H04
HMS2096G03
nsc-756692
pharmakon1600-01500187
nsc756692
tox21_110369
dtxcid902812
dtxsid4022812 ,
HMS2236D07
q0mqd1073q ,
higroton
clortalidone
chlorthalidone [usan:usp]
5-22-07-00602 (beilstein handbook reference)
clortalidona
unii-q0mqd1073q
chlortalidone [inn]
CCG-38917
S3074
2-chloro-5-(1,3-dihydroxy-1h-isoindol-1-yl)benzene-1-sulfonamide
gtpl7147
HMS3372A07
chlorthalidone [usan]
regroton component chlorthalidone
chlorthalidone [hsdb]
chlortalidone [jan]
demi-regroton component chlorthalidone
chlorthalidone component of regroton
chlorthalidone [mi]
chlorthalidone component of tenoretic
clorpres component chlorthalidone
chlortalidone [mart.]
chlorthalidone component of kerledex
chlorthalidone component of combipres
chlorthalidone [usp monograph]
lopressidone component chlorthalidone
chlortalidone [ep monograph]
chlorthalidone component of demi-regroton
tenoretic component chlorthalidone
kerledex component chlorthalidone
chlorthalidone [orange book]
combipres component chlorthalidone
chlorthalidone component of lopressidone
chlortalidone [ep impurity]
chlortalidone [who-dd]
chlorthalidone [vandf]
chlorthalidone [usp-rs]
chlorthalidone component of clorpres
chlortalidone [who-ip]
chlortalidonum [who-ip latin]
HY-15833
NC00690
SCHEMBL26234
NCGC00094616-07
tox21_110369_1
KS-1342
(.+/-.)-hygroton
2-chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1h-isoindol-1-yl)benzenesulfonamide #
2-chloro-5-(1-hydroxy-3-oxo-1h-isoindolinyl)benzenesulfonamide
combipres (salt/mix)
regroton (salt/mix)
oksodolin
(.+/-.)-chlorthalidone
W-104322
2-chloro-5-(1-hydroxy-3-oxoisoindolin-1-yl)benzenesulfonamide
AB00051946_12
OPERA_ID_138
hydroton
chlorthalidone, european pharmacopoeia (ep) reference standard
SR-01000721929-3
sr-01000721929
SR-01000721929-2
chlorthalidone, united states pharmacopeia (usp) reference standard
chlortalidone for peak identification, european pharmacopoeia (ep) reference standard
chlortalidone 1.0 mg/ml in methanol
SBI-0051313.P003
HMS3713G03
Q425289
Z1741981513
mfcd00036257
chlorthalidone (chlortalidone)
74658-80-3
BCP27835
BRD-A26384407-001-15-2
C76474
[(3,5-difluorophenyl)amino](oxo)aceticacid
EN300-18527725
2-chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1h-isoindol-1-yl)-1-benzenesulfonamide
chlortalidone (ep monograph)
chlortalidone (ep impurity)
chlorthalidone (usp-rs)
c03ba04
chlorthalidone (usp monograph)
chlortalidone (mart.)
chlorthalidonechlorthalidone

Excerpt	Reference	Relevance
"Chlorthalidone (CTD) is a thiazide-like diuretic and an effective antihypertensive drug, yet little data exist to support its use in treating hypertension in individuals with advanced CKD."	( Design and Baseline Characteristics of the Chlorthalidone in Chronic Kidney Disease (CLICK) Trial. Agarwal, R; Balmes-Fenwick, M; Cramer, AE; Ouyang, F; Sinha, AD; Tu, W, 2020)	1.54
"Chlorthalidone (CTD) is an antihypertensive drug and exhibits four crystalline forms: I, II, III and IV. "	( Analysis of chlorthalidone polymorphs in raw materials and tablets and the effect of forms I and II on the dissolution properties of drug products. Bonfilio, R; de Araújo, MB; Doriguetto, AC; Leal, JS; Pereira, GR; Santos, OM, 2014)	2.22
"Chlorthalidone is a very effective antihypertensive drug, but it has not been studied prospectively in kidney transplant recipients with hypertension. "	( Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. Hesselink, DA; Hoorn, EJ; Moes, AD; van den Meiracker, AH; Zietse, R, 2017)	3.34
"Chlorthalidone is an antihypertensive drug equally effective as amlodipine after kidney transplantation."	( Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. Hesselink, DA; Hoorn, EJ; Moes, AD; van den Meiracker, AH; Zietse, R, 2017)	3.34

Excerpt	Reference	Relevance
"chlorthalidone has a long terminal half-life in whole blood of 49 h, with peak concentrations occurring 8-10 h after oral dosing."	( Analysis of chlorthalidone in biological fluids by high-performance liquid chromatography using a rapid column cleanup procedure. Esber, HJ; Farina, PR; Hagopian, M; Hay, N; Keirns, JJ; MacGregor, TR, 1984)	1.37
"Chlorthalidone, 12.5-25 mg, has shown cardiovascular benefit, including with MetS and DM."	( Obesity and hypertension: It's about more than the numbers. Ferdinand, KC, 2013)	1.11
"Chlorthalidone has been used sparingly in clinical practice in large measure because it is not readily available in many fixed-dose combination products."	( Chlorthalidone - a renaissance in use? Sica, DA, 2009)	2.52
"Chlorthalidone has been shown to decrease platelet aggregation and vascular permeability and promote angiogenesis in vitro, which is thought to be, in part, the result of reductions in carbonic anhydrase-dependent pathways, including catecholamine-mediated platelet aggregation and downregulation of VEGF-C gene expression."	( Chlorthalidone: the forgotten diuretic. Ezer, M; Goldman, A; Kountz, DS; Mikhail, J, 2012)	2.54
"Chlorthalidone has proven efficacy to reduce cardiovascular morbidity and mortality, yet it is infrequently used in practice. "	( Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Bakris, GL; Cushman, WC; Handley, A; Kupfer, S; Sica, D; Song, E; Weber, MA; White, WB, 2012)	2.07
"Chlorthalidone has significantly reduced stroke and cardiovascular end points in several landmark trials; however, hydrochlorothiazide remains favored in practice."	( Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Bergus, GR; Carter, BL; Ernst, ME; Goerdt, CJ; Phillips, BB; Steffensmeier, JJ; Zimmerman, MB, 2006)	1.29
"chlorthalidone has a long terminal half-life in whole blood of 49 h, with peak concentrations occurring 8-10 h after oral dosing."	( Analysis of chlorthalidone in biological fluids by high-performance liquid chromatography using a rapid column cleanup procedure. Esber, HJ; Farina, PR; Hagopian, M; Hay, N; Keirns, JJ; MacGregor, TR, 1984)	1.37

Excerpt	Reference	Relevance
"Chlorthalidone caused an increase in total serum and low density lipoprotein (LDL) cholesterol, but not in high density lipoprotein (HDL) cholesterol."	( The effect of chlorthalidone on serum lipids and lipoproteins. Holtzman, E; Rosenthal, T; Segal, P, 1980)	1.34

Excerpt	Reference	Relevance
"chlorthalidone treatment with fasting glucose (P < 0.001)."	( Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study. Arnett, DK; Barzilay, JI; Boerwinkle, E; Davis, BR; Eckfeldt, JH; Ford, CE; Irvin, MR; Kabagambe, EK; Lynch, AI; Tiwari, HK, 2010)	1.08
"The chlorthalidone/reserpine-treated group required fewer titrations than the hydrochlorothiazide/reserpine-treated group."	( Chlorthalidone plus reserpine versus hydrochlorothiazide plus reserpine in a stepped-care approach to the treatment of essential hypertension. Finnerty, FA, )	2.05
"Chlorthalidone treatment reduced the high plasma sodium content observed in DOCA-salt rats to the same levels observed in normotensive control groups."	( Chlorthalidone reduces vascular hyperresponsiveness in DOCA-salt hypertensive rats. Bissoli, NS; Cabral, AM; Carvalhinho, FB; Musso, MN; Vasquez, EC, 1992)	2.45
"Chlorthalidone treatment reduced arterial hypertension in DOC-salt treated rats (from 160 +/- 7 to 127 +/- 5 mmHg)."	( Chlorthalidone alters the vascular reactivity of DOC-salt hypertensive rats to norepinephrine. Bissoli, NS; Cabral, AM; Carvalhinho, FB; Musso, MN; Vasquez, EC, 1990)	2.44
"Chlorthalidone treatment resulted in a 90.1 per cent decrease from predicted rates and both dosages yielded similar results."	( Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. Citron, JT; Dolman, LI; Ettinger, B; Livermore, B, 1988)	2.44

Excerpt	Reference	Relevance
" The adverse experience safety data derived from 18 double-blind trials (n = 2884) were evaluated."	( Safety profile of celiprolol. Lamon, KD, 1988)	0.27
" With the lower-dose compound, the metabolic side effect of hypokalemia was less of a problem and there was no evidence of glucose intolerance."	( Efficacy and reduced metabolic side effects of a 15-mg chlorthalidone formulation in the treatment of mild hypertension. A multicenter study. Gens, JD; Green, DE; Mehrotra, KG; Mookherjee, S; Vardan, S; Willsey, GA, )	0.38
" No clinically significant abnormalities in laboratory variables and no serious adverse effects were encountered."	( Randomised double-blind comparative study of efficacy and safety of hydroflumethiazide and reserpine and chlortalidone and atenolol in the treatment of mild to moderate hypertension in black patients. Maharaj, B; van der Byl, K, 1993)	0.29
" In addition, combination therapy enhances tolerability because one drug of fixed combination can antagonize some of the adverse effects of the second drug."	( [Fixed-dose combination therapy: reduction of side effects with enhanced tolerance and antihypertensive efficacy]. Gómez Guindal, JA; González Lama, I; González Maqueda, I, 1999)	0.3
" Safety and tolerability evaluations were based on adverse events, ECG and laboratory tests, and clinically relevant reports of abnormalities."	( Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study. Alberici, M; Lembo, G; Payeras, AC; Sladek, K, 2007)	0.34
" The most common adverse events, irrespective of treatment, were dizziness (8."	( Safety, tolerability, and efficacy of azilsartan medoxomil with or without chlorthalidone during and after 8 months of treatment for hypertension. Barger, B; Handley, A; Kipnes, MS; Lloyd, E; Roberts, A, 2015)	0.65
" Adverse events (AEs) were reported in 75."	( Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study. Barger, B; Handley, A; Lloyd, E; Roberts, A, 2016)	0.43
" Treatment-emergent adverse events/serious adverse events occurred in 78."	( Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide. Barger, B; Cushman, WC; Handley, A; Lloyd, E; Neutel, JM, 2017)	0.68
" The most commonly reported adverse events are dizziness, headache, fatigue, upper respiratory tract infection and urinary tract infection."	( Evaluating the Safety and Tolerability of Azilsartan Medoxomil Alone or in Combination With Chlorthalidone in the Management of Hypertension: A Systematic Review. Antonopoulos, AS; Katsi, V; Michalakeas, C; Soulaidopoulos, S; Tousoulis, D; Tsioufis, K; Vlachopoulos, C, 2021)	0.84
"The outcomes of interest were adverse kidney events (ie, eGFR decline ≥30%, dialysis, or kidney transplantation), cardiovascular events (composite of myocardial infarction, coronary revascularization, heart failure, or atrial fibrillation), all-cause mortality, and electrolyte anomalies (ie, sodium or potassium levels outside reference ranges)."	( Comparison of Clinical Outcomes and Safety Associated With Chlorthalidone vs Hydrochlorothiazide in Older Adults With Varying Levels of Kidney Function. Bugeja, A; Burns, K; Canney, M; Edwards, C; Hundemer, GL; Knoll, G; Petrcich, W; Sood, MM, 2021)	0.86
" In terms of safety, no special adverse events and clinically significant results were noted, and all dose groups of the triple combination are considered safe for use in essential hypertension patients."	( Efficacy and safety of low-dose antihypertensive combination of amlodipine, telmisartan, and chlorthalidone: A randomized, double-blind, parallel, phase II trial. Ahn, JC; Cho, EJ; Han, SH; Kang, SM; Kim, KH; Kim, KI; Kim, SY; Kim, W; Kim, YJ; Park, CG; Park, SJ; Park, SM; Shin, J; Shin, JH; Sohn, IS; Sung, JH; Sung, KC, 2022)	0.94
" This systematic review aims at presenting a complete overview of evidence over the benefits and risks of alpha-1 antagonist treatment in people ≥ 65 years, and at deriving recommendations for a safe application of alpha-1 antagonists in older adults from the evidence found."	( Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing. Kienberger, G; Mann, E; Mansbart, F; Sönnichsen, A, 2022)	0.72
" Analyses of the risk profile indicated an increase in vasodilation related adverse events and sexual adverse events for some agents."	( Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing. Kienberger, G; Mann, E; Mansbart, F; Sönnichsen, A, 2022)	0.72
" Third-standard-dose triple antihypertensive combination therapy demonstrated early effective BP control compared to third-standard-dose dual combination therapies, without increasing adverse drug reactions in patients with mild-to-moderate hypertension."	( Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension. Cho, DK; Cho, GY; Cho, JM; Heo, JH; Hong, SJ; Jeong, MH; Jung, JA; Kim, DH; Kim, SH; Kim, SY; Kim, W; Kwon, K; Lee, HY; Lee, JB; Lim, SW; Park, K; Park, S; Pyun, WB; Rha, SW; Rhee, MY; Shin, J; Sung, KC, 2023)	0.91
" There are no serious adverse event and no one discontinued medication due to adverse event."	( Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial. Ahn, Y; Cha, KS; Chang, K; Cho, EJ; Choi, DJ; Choi, SY; Doh, JH; Hong, SJ; Hong, SP; Hwang, JY; Hyon, MS; Ihm, SH; Kang, WC; Kim, HS; Kim, MH; Kim, SH; Kim, WS; Kim, YH; Kwon, K; Lee, JH; Lee, N; Lim, SW; Rhee, MY; Shin, J; Son, JW; Yoo, BS, 2023)	1.13

Excerpt	Reference	Relevance
"A pharmacodynamic approach was employed to examine the diuretic effect of chlorthalidone in beagle dogs and to identify parameters necessary for optimization of an oral dosage formulation of this drug."	( Chlorthalidone pharmacodynamics in beagle dogs. Esber, HJ; Farina, PR; Horhota, ST; Keirns, JJ; MacGregor, TR; Matzek, KM, 1985)	1.94
" A linear relationship was observed and on the basis of this, a pharmacokinetic model to explain the long and variable biological half life of chlorthalidone is proposed and discussed."	( Pharmacokinetics of chlorthalidone. Dependence of biological half life on blood carbonic anhydrase levels. Mulley, BA; Parr, GD; Rye, RM, 1980)	0.79
"A potential pharmacokinetic interaction between the beta-blocking drug, metoprolol, and the diuretic, chlorthalidone, has been investigated in three single or multiple dose studies in healthy volunteers."	( Comparative pharmacokinetic profiles of metoprolol and chlorthalidone administered alone or in combination to healthy volunteers. Gerardin, A; Godbillon, J; John, VA; Theobald, W, 1983)	0.73
" From pharmacokinetic aspects therefore a fixed combination of two synergistic antihypertensive agents can be considered as useful."	( [Pharmacokinetics of clonidine and chlorthalidone following subacute administration of a fixed combination compared with a sustained release formulation of clonidine alone (author's transl)]. Arendt, G; Arndts, D; Doevendans, J; Rippen, G, 1981)	0.54
"The pharmacodynamic properties of meloxicam, a new nonsteroidal antiinflammatory drug (NSAID), that go beyond those typical of an NSAID were examined."	( General pharmacology of meloxicam--Part II: Effects on blood pressure, blood flow, heart rate, ECG, respiratory minute volume and interactions with paracetamol, pirenzepine, chlorthalidone, phenprocoumon and tolbutamide. Engelhardt, G; Homma, D; Schlegel, K; Schnitzler, C; Utzmann, R, 1996)	0.49
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" Based on the 90% confidence interval of the individual ratios for Cmax and AUC0-inf, it was concluded that the test formulation is bioequivalent to the reference Hyzaar formulation with respect to the rate and extent of absorption of both LOS and HCTZ."	( Simultaneous determination of losartan and hydrochlorothiazide in human plasma by LC/MS/MS with electrospray ionization and its application to pharmacokinetics. Andraus, MH; Azevedo, CP; Borges, BC; Borges, NC; Moreira, RF; Moreno, RA; Salvadori, MC, 2009)	0.35
" Our results indicated that the serial sampling technique would reduce the number of animals and also compound usage, as well as improve the quality of pharmacokinetic data."	( A modified serial blood sampling technique and utility of dried-blood spot technique in estimation of blood concentration: application in mouse pharmacokinetics. Kurawattimath, V; Mandlekar, S; Mariappan, TT; Pocha, K; Trivedi, RK, 2012)	0.38
"Population pharmacokinetic and exposure-response models for azilsartan medoxomil (AZL-M) and chlorthalidone (CLD) were developed using data from an 8-week placebo-controlled phase 3, factorial study of 20, 40, and 80 mg AZL-M every day (QD) and 12."	( Population Pharmacokinetics and Exposure-Response of a Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With Stage 2 Hypertension. Kupfer, S; Tsai, MC; Vakilynejad, M; Wu, J, 2016)	0.87
" Therefore, pharmacokinetic drug interactions are an important issue in combination therapy for hypertension."	( Evaluation of a Pharmacokinetic Interaction between Telmisartan and Chlorthalidone in Healthy Male Adult Subjects. Gwon, MR; Kang, WY; Kim, BK; Kim, HJ; Lee, HW; Lee, J; Lim, MS; Ohk, B; Seong, SJ; Yang, DH; Yoon, YR, 2016)	0.67
"Thus, in this study, there was no significant pharmacokinetic interaction between telmisartan and chlorthalidone."	( Evaluation of a Pharmacokinetic Interaction between Telmisartan and Chlorthalidone in Healthy Male Adult Subjects. Gwon, MR; Kang, WY; Kim, BK; Kim, HJ; Lee, HW; Lee, J; Lim, MS; Ohk, B; Seong, SJ; Yang, DH; Yoon, YR, 2016)	0.89
" In cohort 1, the fed-fasted ratios for AUC0-inf and Cmax were 108."	( Effects of Food Intake on the Pharmacokinetics of Azilsartan Medoxomil and Chlorthalidone Alone and in Fixed-Dose Combination in Healthy Adults. Dudkowski, C; Karim, A; Munsaka, M, 2016)	0.66
" The combination of AZ and CLT had greater BP lowering effect compared to AZ or CLT alone, despite of no pharmacokinetic interaction between two drugs."	( Pharmacokinetic-pharmacodynamic modeling of the antihypertensive interaction between azilsartan medoxomil and chlorthalidone in spontaneously hypertensive rats. Bhateria, M; Bhatta, RS; Hanif, K; Jain, M; Kumar Puttrevu, S; Ramakrishna, R, 2017)	0.67
" The objective of this study was to compare the pharmacokinetic (PK) profiles of HCP1401, a fixed-dose combination of amlodipine 5 mg, losartan 100 mg, and chlorthalidone 25 mg, with the separate components (loose combination) of amlodipine/losartan 5/100 mg and chlorthalidone 25 mg."	( Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan and Chlorthalidone Compared to Concurrent Administration of the Separate Components. Choi, Y; Chung, JY; Jeon, I; Jung, J; Moon, SJ; Park, SI; Yu, KS, 2022)	1.15

Excerpt	Reference	Relevance
" It is concluded that the doses employed both of propranolol and practolol had a good and approximately equal antihypertensive effect when combined with chlorthalidone treatment."	( Comparison of the antihypertensive effect of propranolol and practolol combined with chlorthalidone. Boer, P; Geyskes, GG; Mees, EJ; Stutterheim, A, 1975)	0.68
" Metoprolol in combination with chlorathalidone appears to be an effective and well-tolerated treatment for mild and moderate hypertension in patients not responding to chlorthalidone alone."	( A controlled study on the anti-hypertensive effect of a new beta-adrenoreceptor-blocking drug, metoprolol, in combination with chlorthalidone. Jäättelä, A; Pyörälä, K, 1976)	0.66
"This report examines the effect of weight loss, alone and in combination with drugs, on diastolic blood pressure change in the Trial of Antihypertensive Interventions and Management (TAIM), which is a randomized, multicenter, placebo-controlled clinical trial of drug and diet combinations in the treatment of mild hypertension among 787 patients."	( The Trial of Antihypertensive Interventions and Management (TAIM) study. Adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension. Blaufox, MD; Davis, BR; Langford, HG; Oberman, AS; Wassertheil-Smoller, S; Wylie-Rosett, J, 1992)	0.28
"In a double-blind trial, 545 out-patients with essential hypertension received 25 mg/day chlorthalidone alone (274 patients) or in fixed combination with 200 mg/day slow-release metoprolol (271 patients) for 8 weeks."	( Chlorthalidone alone or in fixed combination with slow-release metoprolol in the management of arterial hypertension: a long-term study of 545 patients. Alberti, D; Bichisao, E; Gambini, O; Merlini, L; Pollavini, G, )	1.8
"The study was a comparison of the effects on respiratory function produced by four antihypertensive agents with receptor-blocking properties (atenolol, oxprenolol, labetalol, metoprolol), when used in combination with a diuretic (chlorthalidone) in four homogeneous groups of hypertensive patients also suffering from chronic obstructive lung disease."	( Respiratory effects of four adrenergic blocking agents combined with a diuretic in treating hypertension with concurrent chronic obstructive lung disease. Dal Negro, RW; Pomari, C; Trevisan, F; Turco, P; Zoccatelli, O, 1986)	0.45
"The influence of a once daily dose of 200 mg celiprolol alone and in combination with 12."	( [Uricosuric action of a new beta receptor blocker-diuretic drug combination]. Brandstetter, G; Eslaminejad, S; Hoffmann, H; Maderbacher, H, 1986)	0.27
"To evaluate the hypotensive efficacy of Verapamil alone and combined with diuretic, in the treatment of essential hypertension in elderly patients, we studied 54 patients, mean age 67."	( [Hypotensive efficacy of verapamil alone and in combination with a diuretic in the treatment of essential hypertension in geriatric patients]. Achilli, L; D'Amico, F; Latini, R; Lombi, V; Pierandrei, G, 1987)	0.27
"Exchangeable sodium, blood volume, plasma norepinephrine, epinephrine, renin levels, and pressor responses to infused norepinephrine or angiotensin II were assessed in 10 patients with essential hypertension on placebo, following six to eight weeks of monotherapy with nifedipine, 3 X 10-20 mg/day, and after six to eight weeks on nifedipine combined with the diuretic chlorthalidone, 25 to 50 mg/day."	( Pressor factors and cardiovascular pressor responsiveness after short-term antihypertensive therapy with the calcium antagonist nifedipine alone or combined with a diuretic. Beretta-Piccoli, C; Bianchetti, MG; Bomio, F; Luisoli, S; Marone, C; Weidmann, P, 1984)	0.44
" Metoprolol in combination with chlorthalidone appears to be an effective and well-tolerated treatment for mild and moderate hypertension in those patients not responding to chlorthalidone alone."	( A controlled study on the antihypertensive effect of a new beta-adrenergic receptor blocking drug, metoprolol, in combination with chlorthalidone. Jäättelä, A; Pyörälä, K, 1976)	0.74
" This study provides a direct comparison of chlorthalidone with hydrochlorothiazide, each combined with the angiotensin receptor blocker azilsartan medoxomil, on blood pressure reduction and control rates."	( Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Bakris, GL; Cushman, WC; Handley, A; Kupfer, S; Sica, D; Song, E; Weber, MA; White, WB, 2012)	0.89
"Chlorthalidone combined with azilsartan medoxomil provides better blood pressure reduction and a higher likelihood of achieving blood pressure control than hydrochlorothiazide combined with azilsartan medoxomil."	( Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Bakris, GL; Cushman, WC; Handley, A; Kupfer, S; Sica, D; Song, E; Weber, MA; White, WB, 2012)	2.07
" This trial aims to investigate the efficacy of chlorthalidone and hydrochlorothiazide, in combination with amiloride at different doses, for initial management of patients with primary hypertension."	( Efficacy of chlorthalidone and hydrochlorothiazide in combination with amiloride in multiple doses on blood pressure in patients with primary hypertension: a protocol for a factorial randomized controlled trial. Bottino, LG; Ferrari, F; Fuchs, FD; Fuchs, SC; Helal, L; Martins, VM, 2019)	1.15
" Chlorthalidone and hydrochlorothiazide, in combination with amiloride in multiple doses, will be tested in terms of blood pressure lowering efficacy and safety."	( Efficacy of chlorthalidone and hydrochlorothiazide in combination with amiloride in multiple doses on blood pressure in patients with primary hypertension: a protocol for a factorial randomized controlled trial. Bottino, LG; Ferrari, F; Fuchs, FD; Fuchs, SC; Helal, L; Martins, VM, 2019)	1.8
" Azilsartan medoxomil in combination with the older diuretic chlorthalidone (CLD) in fixed-doses of AZM/CLD 40/12."	( Evaluating the Safety and Tolerability of Azilsartan Medoxomil Alone or in Combination With Chlorthalidone in the Management of Hypertension: A Systematic Review. Antonopoulos, AS; Katsi, V; Michalakeas, C; Soulaidopoulos, S; Tousoulis, D; Tsioufis, K; Vlachopoulos, C, 2021)	1.08

Excerpt	Reference	Relevance
"In this comparative bioavailability study in 12 healthy volunteers the blood level profiles and urinary recoveries of both atenolol and chlorthalidone were studied following the administration of the drugs as a fixed combination ('Tenoret 50'), as a free combination, and individually, at doses of 50 mg atenolol and 12."	( Bioavailability in man of atenolol and chlorthalidone from a combination formulation. Fitzsimons, TJ; Holmes, BH; McAinsh, J; Young, J, )	0.6
" These studies led to the development of a relevant pharmacokinetic model which highlighted the importance of the oral absorption rate on the diuretic efficacy of chlorthalidone."	( Chlorthalidone pharmacodynamics in beagle dogs. Esber, HJ; Farina, PR; Horhota, ST; Keirns, JJ; MacGregor, TR; Matzek, KM, 1985)	1.91
"The relative bioavailability of chlorthalidone from rapidly dissolving, stabilized, amorphous 15- and 25-mg formulations was compared in 24 normal adult male volunteers to the 25-mg market standard tablet and a 25-mg oral reference solution."	( Relative bioavailability of chlorthalidone in humans after single oral doses. Farina, PR; Horhota, ST; Keirns, JJ; MacGregor, TR, 1985)	0.85
"The bioavailability of two commercial preparations of chlorthalidone was studied in healthy male subjects."	( Relative bioavailability of chlorthalidone in humans: adverse influence of polyethylene glycol. Benet, LZ; Blume, CD; Holford, NH; Lin, ET; Williams, RL, 1982)	0.81
"In this comparative bioavailability study in 12 healthy volunteers the blood level profiles and urinary recoveries of both atenolol and chlorthalidone were studied following the administration of the drug as a fixed combination ('Tenoretic'), as a free combination, and individually, at doses of 100 mg atenolol, and 25 mg chlorthalidone."	( Bioavailability in man of atenolol and chlorthalidone from a combination formulation. Bastain, W; Harry, JD; McAinsh, J; Young, J, )	0.6
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."	( QSAR model for drug human oral bioavailability. Topliss, JG; Yoshida, F, 2000)	0.31
" The bioavailability of the two formulations was compared through the 90% confidence intervals (C."	( Comparative bioavailability of two formulations containing atenolol and chlortalidone associated in a 4:1 fixed combination. Crivelli, F; Dal Bo, L; Ismaili, S; Marzo, A; Mazzucchelli, P; Monti, NC; Porziotta, E; Ronchi, C; Tettamanti, RA; Uhr, MR, 2000)	0.31
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
"Supersaturating drug delivery systems (SDDS), as solid dispersions (SDs), stand out among strategies to enhance bioavailability of poorly soluble drugs."	( Investigation of novel supersaturating drug delivery systems of chlorthalidone: The use of polymer-surfactant complex as an effective carrier in solid dispersions. França, MT; Klüppel Riekes, M; Munari Oliveira Pinto, J; Nicolay Pereira, R; Stulzer, HK, 2018)	0.72
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" Dosage order was randomized and double-blind."	( Cardiovascular response to exercise under increasing doses of chlorthalidone. Ogilvie, RI, 1976)	0.5
" 4) In the management of essential moderate or severe hypertension is preferable to employ a mild dosage of betablockers and diuretics, rather than use higher doses of a single agent."	( [The role of renin after betablocking diuretic and vasodilator treatment in essential hypertension (author's transl)]. Fusco, M; Lombardo, M; Valente, D, 1979)	0.26
"1 The hypotensive effect of single daily dosing with atenolol 100 mg and chlorthalidone 25 mg given alone or in combination has been assessed in a double-blind, crossover, placebo controlled trial in fifteen hypertensive patients."	( Atenolol and chlorthalidone in combination for hypertension. Bateman, DN; Bulpitt, CJ; Dean, CR; Dollery, CT; Mucklow, JC, 1979)	0.86
" However, patient compliance might be considerably improved with the once-daily dosage schedule of the fixed combination."	( Antihypertensive effect of oxprenolol and chlorthalidone in fixed combination, given once daily. Buoninconti, R; Motolese, M; Rubegni, M, 1979)	0.52
" The concentration of unchanged chlorthalidone was analyzed over a 100 to 220 h period in plasma, red blood cells, urine and faeces after both dosage forms."	( Absolute bioavailability of chlorthalidone in man: a cross-over study after intravenous and oral administration. Fleuren, HL; Thien, TA; van Rossum, JM; Verwey-van Wissen, CP, 1979)	0.84
" If the MAP was more than 108 mm Hg at the end of the week, dosage of the beta-blocker was doubled the following week; when necessary, doubling was repeated to a maximum dose of 640 mg propranolol and 400 mg atenolol daily."	( Effects of atenolol and propranolol when added to long-term antihypertensive diuretic therapy. Boer, P; Dorhout Mees, EJ; Geyskes, GG; van Rooijen, GJ, 1979)	0.26
"A reliable and selective high-pressure liquid chromatographic procedure for the quantitative determination of chlorthalidone in pharmaceutical dosage forms is described."	( Quantitative determination of chlorthalidone in pharmaceutical dosage forms by high-pressure liquid chromatography. Moody, JE; O'Hare, MJ; Tan, E, 1979)	0.76
" A reduction in dosage from 50 mg daily to 50 mg three times a week produced no significant changes in the diastolic or mean blood pressures though the systolic blood pressure was moderately increased."	( Effect of different doses of chlorthalidone on blood pressure, serum potassium, and serum urate. Bengtsson, C; Johnsson, G; Sannerstedt, R; Werkö, L, 1975)	0.55
"750 mg/kg body weight the dose-response curve of orally administered xipamide for the increase of excretion of urine, sodium and potassium ion and chloride during 24 h is described."	( [The saluretic effect of xipamide (4-chloro-5-sulfamoyl-2',6'-salicyloxylilide) in normal subjects]. Hempelmann, FW; Leuschner, F; Liebenow, W, 1975)	0.25
"The antihypertensive effect of a fixed dosage combination of the cardioselective beta-adrenoceptor blocker, atenolol, and the oral thiazide-like diuretic, chlorthalidone (Tenoretic) was studied in 24 hypertensive Nigerians in a double-blind, cross-over comparison with three other treatments."	( Assessment of a fixed-dosage combination of atenolol and chlorthalidone (Tenoretic) in hypertensive Nigerians. Aderounmu, AF; Falase, AO; Salako, LA; Walker, O, 1990)	0.72
" Clonidine-related side effects are still evident, but the overall tolerance profile for this reduced dosage of the drug appears to be favorable."	( Low-dose clonidine administration in the treatment of mild or moderate essential hypertension: results from a double-blind placebo-controlled study (Clobass). The Clobass Study Group. , 1990)	0.28
" Prophylactic medication for asthma was given in constant dosage for a month before the study and throughout the study."	( A comparison of celiprolol and chlorthalidone in hypertensive patients with reversible bronchial obstruction. Capone, P; Clauzel, AM; Dorow, P; Mathieu, M; Mayol, R, 1986)	0.56
" The results demonstrated a wide margin of safety for celiprolol over the recommended dosage range of 200 to 600 mg once daily."	( Safety profile of celiprolol. Lamon, KD, 1988)	0.27
" Prophylactic medication for asthma was given at a constant dosage for 1 month before the study and throughout the study."	( Celiprolol--review of airways studies. Dorow, P, 1988)	0.27
"01), whereas the groups receiving low and high dosage magnesium hydroxide showed 73."	( Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. Citron, JT; Dolman, LI; Ettinger, B; Livermore, B, 1988)	1.72
" It is less clear, however, whether renin-angiotensin II stimulation is the cause of the flat blood pressure dose-response relationship to diuretics."	( Plasma renin activity does not predict the antihypertensive efficacy of chlorthalidone. Bartolomei, G; Cagianelli, MA; Cinotti, G; Innocenti, P; Loni, C; Papi, L; Pedrinelli, R; Saba, G; Saba, P; Salvetti, A, 1987)	0.51
"5 mg/day of metolazone or 25 mg/day of chlorthalidone are effective antihypertensive agents but that blood pressure lowering may be inconsistent at these dosage levels."	( Low-dose diuretic therapy for hypertension. Moser, M, 1986)	0.54
" After 3 and 6 months of maintenance therapy, blood pressures were measured 24 hours after the previous day's dosing to evaluate the persistence of the antihypertensive effect."	( The management of severe hypertension with minoxidil in a once-a-day treatment regimen. Bayley, A; Fraser, HS; Hassell, TA; Nicholson, GD, 1985)	0.27
"The purpose of this study was to determine the effects on blood pressure and selected biochemical measures of reducing the dosage of chlorthalidone from 100 mg to 50 mg."	( Beneficial effects from systematic dosage reduction of the diuretic, chlorthalidone: a randomized study within a clinical trial. Allen, R; Bailey-Hoffman, G; Case, J; Childs, J; Grimm, RH; Hulley, SB; Kousch, D; McDonald, M; McGill, E; Neaton, JD, 1985)	0.71
" Dosage was a single tablet per day given in the morning."	( Atenolol and chlorthalidone in combination in the management of older hypertensive patients: a randomized clinical trial. Backhouse, CI; Edwards, KG; Hosie, J; Tweed, JA, 1985)	0.64
" When other variables were controlled for, medicated men had significantly higher serum zinc levels, and men on the highest dosage of chlorthalidone had higher hair zinc levels than all other men."	( Effect of chlorthalidone on zinc levels, testosterone, and sexual function in man. Cohen, RD; Geissler, AH; Turnlund, JR, 1986)	0.88
"Thiazides are considered to be effective in preventing recurrence of various types of nephrolithiasis, but the optimum dosage has not been established."	( [Optimal dosage of chlorthalidone in the prevention of the recurrence of nephrolithiasis is 25 mg per day]. Bugnon, JM; Burckhardt, P; Jacquet, AF; Jaeger, P; Portmann, L, 1986)	0.6
"A pharmacodynamic approach was employed to examine the diuretic effect of chlorthalidone in beagle dogs and to identify parameters necessary for optimization of an oral dosage formulation of this drug."	( Chlorthalidone pharmacodynamics in beagle dogs. Esber, HJ; Farina, PR; Horhota, ST; Keirns, JJ; MacGregor, TR; Matzek, KM, 1985)	1.94
" Triamterene seemed ineffective in the dosage used (50 mg twice daily)."	( Potassium-sparing agents during diuretic therapy in hypertension. Brien, TG; Canning, BS; Donohoe, JF; Healy, JJ; McKenna, TJ; Muldowney, FP, 1971)	0.25
" Results obtained show that the fixed combination oxprenolol 80 mg plus chlorthalidone 10 mg can be safely administered also in the elderly hypertensive patients, without risk of cardiovascular complications, allowing satisfactory blood pressure control, with a simple dosage schedule, thus improving patient compliance to the therapy."	( [Effectiveness of treatment with beta-blocking agents and diuretics in fixed combination, in aged hypertensive patients]. Andreoni, A; Paciaroni, E; Quattrini, L; Saccomanno, G, 1980)	0.49
" The double regimen caused a drop in pressure of 16/11 mm Hg after one month (daily doses 25 mg chlorthalidone, 103 +/- 25 mg propranolol), and this reduction did not change at the third month in spite of dosage increases (daily doses 25 mg chlorthalidone, 222 +/- 77 mg propranolol)."	( A crossover trial of oxdralazine in hypertension. Criscuolo, D; Galli, F; Salvadeo, A; Segagni, S; Villa, G, 1983)	0.48
" Analysis of variance did not reveal differences between the four captopril dosing schedules (1st trial), or between the two captopril dosing schedules (2nd trial)."	( Low-dose captopril therapy in mild and moderate hypertension. Randomized comparison of twice daily vs three times daily doses. Bentivoglio, M; Corea, L; Verdecchia, P, )	0.13
" It is therefore concluded that the relationship between the serum chlorthalidone level and the fall in serum potassium level is in keeping with the flat dose-response curves for the thiazide and phthalimide diuretics."	( The effects of two combinations of a beta-blocker and a diuretic on diuresis in normal subjects. Schoeman, HS; Sommers, DK; van Wyk, M, 1984)	0.5
" Preincubation with IN or C did not affect the dose-response curve of NA-induced contractions."	( A comparative study on possible calcium antagonistic properties of indapamide and other drugs potentially interfering with calcium transport in isolated vascular smooth muscle. De Wildt, DJ; Hillen, FC, 1984)	0.27
" Prompted by these observations, the dosage of chlorthalidone (monotherapy) was decreased in a stepwise fashion and then discontinued after the diastolic BP had been maintained below 85 mm Hg for 6 months in 67 patients with mild systemic hypertension (diastolic BP 92 to 104 mm Hg)."	( Step-down treatment of mild systemic hypertension. Finnerty, FA, 1984)	0.52
" They had simultaneously started therapy with, or increased the dosage of, chlorthalidone or hydrochlorothiazide for the treatment of hypertension."	( Serum cholesterol during treatment of hypertension with diuretic drugs. Ames, RP; Peacock, PB, 1984)	0.5
" This can be obtained by selection of the appropriate dosage regimen for a particular diuretic, such as once daily administration for "long-acting" and twice daily for "short-acting" thiazide-type diuretics."	( Long-acting and short-acting diuretics in mild essential hypertension. Chalmers, JP; Graham, JR; West, MJ; Wing, LM, 1982)	0.26
" The once daily dosing schedule may considerably improve patient's compliance."	( A fixed combination of metoprolol slow-release and chlorthalidone, given once daily, in the long-term treatment of arterial hypertension. Bichisao, E; Floris, B; Franchetta, G; Palestini, N; Sonaglioni, G; Verdecchia, P, 1982)	0.52
" Coadministration of acetazolamide with 14C-labeled indapamide to rats, resulted in a 5-fold drop in the blood levels of total radioactivity, relative to rats dosed with [14C]indapamide alone."	( Effects of competitive red blood cell binding and reduced hematocrit on the blood and plasma levels of [14C]Indapamide in the rat. Lettieri, JT; Portelli, ST, 1983)	0.27
" Pindolol and propranolol lowered PRA comparably at equivalent dosages, although this effect was not consistently observed in all studies or at all dosage levels."	( Pindolol: effects on blood pressure and plasma renin activity. Bennett, CM; Glassock, RJ; Gonasun, L; Hamilton, B; Kirkendall, W; Maxwell, M; Weitzman, RE; Winer, N, 1982)	0.26
" The dosage was individualized on the basis of hypotensive response and side effects until an acceptable blood pressure was achieved."	( Use of the the combination labetalol plus chlorthalidone in essential arterial hypertension therapy. Rossi, AG, 1981)	0.53
" After 2 week's medication, a decline in blood pressure was noted in all dosage groups and this was maximal by 4 weeks."	( Chlorthalidone in mild hypertension - dose response relationship. Humphries, IS; Mayhew, SR; Russell, JG, 1981)	1.71
" The remaining patients of both groups double the corresponding dosage after the first 4 weeks."	( A fixed combination of oxprenolol slow-release and chlorthalidone once daily in treatment of mild to moderate hypertension. Agabiti-Rosei, E; Buoninconti, R; Carotti, A; Fariello, R; Innocenti, P; Motolese, M; Muiesan, G; Toso, M; Valori, C, 1981)	0.51
" Once-daily propranolol dosage was well tolerated and possibly gave less rise to the troublesome side effect of vivid dreaming."	( One and three doses of propranolol a day in hypertension. Boer, P; Dorhout Mees, EJ; Geyskes, GG; van Asten, P; van den Brink, G, 1980)	0.26
" throughout the study; the remaining doubled the corresponding dosage after the first 2 weeks."	( Antihypertensive activity of a fixed combination of oxprenolol and chlorthalidone in mild to moderate arterial hypertension. Agabiti-Rosei, E; Carotti, A; Innocenti, P; Montervino, C; Motolese, M; Muiesan, G; Solinas, E; Toso, M, 1980)	0.5
" After 3 months the drug dosage was doubled if the systolic blood pressure goal (SBP < 160 mmHg and SBP reduction of at least 20 mmHg) had not been reached."	( Antihypertensive efficacy and tolerability of different drug regimens in isolated systolic hypertension in the elderly. Alli, C; Avanzini, F; Bettelli, G; Colombo, F; Corso, R; Mariotti, G; Radice, M; Tognoni, G; Torri, V, 1994)	0.29
" If the DBP did not reach 90 mmHg after four weeks, the dosage was doubled."	( Randomised double-blind comparative study of efficacy and safety of hydroflumethiazide and reserpine and chlortalidone and atenolol in the treatment of mild to moderate hypertension in black patients. Maharaj, B; van der Byl, K, 1993)	0.29
" Dose-response (10(-7)-10(-4) M) effects of indapamide or chlorthalidone on reperfusion-induced arrhythmias, coronary flow, and heart rate (HR) were evaluated in a randomized blinded fashion."	( Influence of indapamide and chlorthalidone on reperfusion-induced ventricular fibrillation in isolated guinea pig hearts. Fiset, C; Kingma, JG; Kingma, ML; Lacoursière, L; Turgeon, J, 1995)	0.83
" In patients showing a decrease of the potassium plasma level, potassium sparing diuretic-amiloride should be added or the dosage of the drug should be halved."	( [Treatment of hypertension with a fixed combination of bopindolol and chlorthalidone (Sandoretic)]. Balazovjech, I; Havlík, V; Havránek, P; Hulínský, V; Kroupa, E; Lánská, V; Nikodýmová, L; Pátek, F; Svihovcová, P; Svítil, F; Widimský, J, 1996)	0.53
" Clinical inputs include agent efficacy, side effects, and compliance with dosing schedules."	( An economic evaluation of the JNC hypertension guidelines using data from a randomized controlled trial. Joint National Committee. Neil, N; Perfetto, E; Ramsey, SD; Sullivan, SD, )	0.13
" Drug dosage was determined in an initial stepped-care titration phase lasting six weeks."	( Reversal of left ventricular hypertrophy following once daily administration of felodipine for two years to elderly subjects with isolated systolic hypertension. De Rosa, ML; Della Guardia, D; Giordano, A; Lionetti, F; Maddaluno, G; Marsicani, N; Vigorito, C, 1999)	0.3
" According to EU guidelines, the bioequivalence of one dosage strength can also cover additional strengths when the pharmacokinetics of a given drug is linearly related with the dose."	( Comparative bioavailability of two formulations containing atenolol and chlortalidone associated in a 4:1 fixed combination. Crivelli, F; Dal Bo, L; Ismaili, S; Marzo, A; Mazzucchelli, P; Monti, NC; Porziotta, E; Ronchi, C; Tettamanti, RA; Uhr, MR, 2000)	0.31
" The components in each mixture have been simultaneously determined in three commercial dosage forms with high accuracy and without interference from commonly encountered excipients and additives."	( Determination of antihypertensive mixtures by use of a chemometrics-assisted spectrophotometric method. Mohamed, Ael-M; Salem, H, 2005)	0.33
" We sought to describe their comparative dose-response relationships for changes in systolic blood pressure (SBP) and potassium."	( Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. Carter, BL; Ernst, ME; Grimm, RH; Zheng, S, 2010)	0.59
" Data were pooled to evaluate the effects on SBP and potassium of both drugs throughout their respective dose-response curves."	( Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. Carter, BL; Ernst, ME; Grimm, RH; Zheng, S, 2010)	0.59
" However, within this dosing range, reductions in potassium can be considered equivalent."	( Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. Carter, BL; Ernst, ME; Grimm, RH; Zheng, S, 2010)	0.59
" This results in dosing large number of animals and generating composite PK profile."	( A modified serial blood sampling technique and utility of dried-blood spot technique in estimation of blood concentration: application in mouse pharmacokinetics. Kurawattimath, V; Mandlekar, S; Mariappan, TT; Pocha, K; Trivedi, RK, 2012)	0.38
" An individually titrated metoprolol dosage (75-300 mg) was used."	( A controlled study on the antihypertensive effect of a new beta-adrenergic receptor blocking drug, metoprolol, in combination with chlorthalidone. Jäättelä, A; Pyörälä, K, 1976)	0.46
" We performed a meta-analysis to characterize the dose-response relationships for 3 commonly prescribed thiazide diuretics, hydrochlorothiazide, chlorthalidone, and bendroflumethiazide, on BP, serum potassium, and urate."	( Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Chaturvedi, N; Hardy, R; Hughes, AD; Peterzan, MA, 2012)	0.81
" Our data show that CTL is associated with greater reduction in 24 h UCa compared to similarly dosed HCTZ."	( Hydrochlorothiazide compared to chlorthalidone in reduction of urinary calcium in patients with kidney stones. Astor, BC; Gundu, V; Jhagroo, RA; Wolfgram, DF, 2013)	0.67
"Two stability-indicating chromatographic methods are described for simultaneous determination of amiloride hydrochloride (AMI), atenolol (ATE), and chlorthalidone (CHL) in combined dosage forms."	( Validated stability-indicating methods for the simultaneous determination of amiloride hydrochloride, atenolol, and chlorthalidone using HPTLC and HPLC with photodiode array detector. Barary, MH; El-Kimary, EI; Hassan, EM; Maher, HM; Youssef, RM, )	0.54
" AZL-M/CLD showed greater systolic BP reductions after initial dosing (P = ."	( Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. Bakris, GL; Hisada, M; Juhasz, A; Kupfer, S; Lloyd, E; Oparil, S; Zhao, L, 2018)	0.72
"Azilsartan Medoxomil (AZL) angiotensin II receptor blocker and chlorthalidone (CLT) were determined by ultraperformance liquid chromatography (UPLC) method in their combined dosage form, they were both subjected to forced degradation studies under extensive stress conditions."	( Stability-Indicating RP-UPLC Method for Simultaneous Determination of Azilsartan Medoxomil and Chlorthalidone in Tablets in the Presence of Its Degradation Products. Hussein, LA; Ibrahim, MA; Magdy, NN, 2019)	0.97
" The aim was to develop an eco-friendly, stability-indicating assay method to determine Chlorthalidone (CLD) and Cilnidipine (CIL) in bulk and tablet dosage form using four different Ultra-Violet (UV) spectrophotometric methods."	( Multiple spectrophotometric determinations of Chlorthalidone and Cilnidipine using propylene carbonate - As a step towards greenness. Chanduluru, HK; Kannaiah, KP; Sugumaran, A, 2022)	1.2

Class	Description
sulfonamide	An amide of a sulfonic acid RS(=O)2NR'2.
isoindoles
monochlorobenzenes	Any member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Chlorthalidone Action Pathway	31	9

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	0.0040	0.0032	45.4673	12,589.2998	AID2517
USP1 protein, partial	Homo sapiens (human)	Potency	28.1838	0.0316	37.5844	354.8130	AID743255
Microtubule-associated protein tau	Homo sapiens (human)	Potency	7.2680	0.1800	13.5574	39.8107	AID1460; AID1468
Smad3	Homo sapiens (human)	Potency	1.5849	0.0052	7.8098	29.0929	AID588855
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	8.4127	0.0010	22.6508	76.6163	AID1224893
cytochrome P450 2D6	Homo sapiens (human)	Potency	38.9018	0.0010	8.3798	61.1304	AID1645840
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	21.1300	0.0006	27.2152	1,122.0200	AID743219
geminin	Homo sapiens (human)	Potency	4.4719	0.0046	11.3741	33.4983	AID624296; AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Carbonic anhydrase 12	Homo sapiens (human)	Ki	29.5355	0.0002	1.1043	9.9000	AID1798598; AID1803141; AID367617
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
Carbonic anhydrase 1	Homo sapiens (human)	Ki	29.5737	0.0000	1.3726	10.0000	AID1798598; AID1803141; AID367608
Carbonic anhydrase 2	Homo sapiens (human)	IC50 (µMol)	0.6770	0.0002	1.1060	8.3000	AID625236
Carbonic anhydrase 2	Homo sapiens (human)	Ki	29.5504	0.0000	0.7236	9.9200	AID1798598; AID1803141; AID367609
Carbonic anhydrase 3	Homo sapiens (human)	Ki	2.8665	0.0002	2.0102	10.0000	AID1798598; AID367610
Carbonic anhydrase 4	Homo sapiens (human)	Ki	1.3230	0.0002	1.9720	9.9200	AID1798598; AID367611
Carbonic anhydrase 6	Homo sapiens (human)	Ki	1.4875	0.0001	1.4710	9.9200	AID1798598; AID367614
Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)	Ki	1.4260	0.0000	1.2725	9.9000	AID1798598; AID367612
Carbonic anhydrase 7	Homo sapiens (human)	Ki	1.2954	0.0002	1.3737	9.9000	AID1798598; AID367615
Carbonic anhydrase 9	Homo sapiens (human)	Ki	29.5376	0.0001	0.7874	9.9000	AID1798598; AID1803141; AID367616
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Carbonic anhydrase 13	Mus musculus (house mouse)	Ki	1.2972	0.0002	1.3974	9.9000	AID1798598; AID367618
Carbonic anhydrase 14	Homo sapiens (human)	Ki	1.8850	0.0002	1.5099	9.9000	AID1798598; AID367619
Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)	Ki	1.2963	0.0000	1.3412	9.9700	AID1798598; AID367613
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
cystic fibrosis transmembrane conductance regulator ATP-binding cassette sub-family C member 7	Homo sapiens (human)	AC50	50.0000	0.0398	15.0025	50.0000	AID743267
Carbonic anhydrase 12	Homo sapiens (human)	Kinact	0.0045	0.0030	0.6674	9.6000	AID328983; AID411536
Carbonic anhydrase 1	Homo sapiens (human)	Kinact	0.3480	0.0100	0.9387	8.6000	AID328974; AID411527
Carbonic anhydrase 2	Homo sapiens (human)	Kinact	0.1380	0.0030	0.7946	10.0000	AID328975; AID411528
Carbonic anhydrase 4	Homo sapiens (human)	Kinact	0.1960	0.0740	2.3934	8.5900	AID328977; AID411530
Carbonic anhydrase 6	Homo sapiens (human)	Kinact	1.3470	0.0009	0.7261	5.3000	AID328980; AID411533
Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)	Kinact	0.9170	0.0200	0.8580	9.4000	AID328978; AID411531
Carbonic anhydrase 7	Homo sapiens (human)	Kinact	0.0028	0.0002	0.2852	5.7300	AID328981; AID411534
Carbonic anhydrase 9	Homo sapiens (human)	Kinact	0.0230	0.0050	0.3197	6.6700	AID328982; AID411535
Carbonic anhydrase 13	Mus musculus (house mouse)	Kinact	0.0150	0.0130	0.5669	8.2300	AID328984; AID411537
Carbonic anhydrase 14	Homo sapiens (human)	Kinact	4.1300	0.0002	1.4495	8.5900	AID328985; AID411538
Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)	Kinact	0.0090	0.0090	0.9231	9.0400	AID328979; AID411532
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
estrous cycle	Carbonic anhydrase 12	Homo sapiens (human)
chloride ion homeostasis	Carbonic anhydrase 12	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 12	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 1	Homo sapiens (human)
morphogenesis of an epithelium	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of cellular pH reduction	Carbonic anhydrase 2	Homo sapiens (human)
angiotensin-activated signaling pathway	Carbonic anhydrase 2	Homo sapiens (human)
regulation of monoatomic anion transport	Carbonic anhydrase 2	Homo sapiens (human)
secretion	Carbonic anhydrase 2	Homo sapiens (human)
regulation of intracellular pH	Carbonic anhydrase 2	Homo sapiens (human)
neuron cellular homeostasis	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of dipeptide transmembrane transport	Carbonic anhydrase 2	Homo sapiens (human)
regulation of chloride transport	Carbonic anhydrase 2	Homo sapiens (human)
carbon dioxide transport	Carbonic anhydrase 2	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 2	Homo sapiens (human)
response to bacterium	Carbonic anhydrase 3	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 3	Homo sapiens (human)
bicarbonate transport	Carbonic anhydrase 4	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 4	Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter taste	Carbonic anhydrase 6	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 6	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Carbonic anhydrase 7	Homo sapiens (human)
positive regulation of cellular pH reduction	Carbonic anhydrase 7	Homo sapiens (human)
neuron cellular homeostasis	Carbonic anhydrase 7	Homo sapiens (human)
regulation of chloride transport	Carbonic anhydrase 7	Homo sapiens (human)
regulation of intracellular pH	Carbonic anhydrase 7	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 7	Homo sapiens (human)
response to hypoxia	Carbonic anhydrase 9	Homo sapiens (human)
morphogenesis of an epithelium	Carbonic anhydrase 9	Homo sapiens (human)
response to xenobiotic stimulus	Carbonic anhydrase 9	Homo sapiens (human)
response to testosterone	Carbonic anhydrase 9	Homo sapiens (human)
secretion	Carbonic anhydrase 9	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 9	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 14	Homo sapiens (human)
response to bacterium	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 12	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 12	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
arylesterase activity	Carbonic anhydrase 1	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 1	Homo sapiens (human)
protein binding	Carbonic anhydrase 1	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 1	Homo sapiens (human)
hydro-lyase activity	Carbonic anhydrase 1	Homo sapiens (human)
cyanamide hydratase activity	Carbonic anhydrase 1	Homo sapiens (human)
arylesterase activity	Carbonic anhydrase 2	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 2	Homo sapiens (human)
protein binding	Carbonic anhydrase 2	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 2	Homo sapiens (human)
cyanamide hydratase activity	Carbonic anhydrase 2	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 3	Homo sapiens (human)
protein binding	Carbonic anhydrase 3	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 3	Homo sapiens (human)
nickel cation binding	Carbonic anhydrase 3	Homo sapiens (human)
protein binding	Carbonic anhydrase 4	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 4	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 4	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 6	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 6	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 7	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 7	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 9	Homo sapiens (human)
protein binding	Carbonic anhydrase 9	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 9	Homo sapiens (human)
molecular function activator activity	Carbonic anhydrase 9	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 14	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 14	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
membrane	Carbonic anhydrase 12	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
apical plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
cytosol	Carbonic anhydrase 1	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 1	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 2	Homo sapiens (human)
cytosol	Carbonic anhydrase 2	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 2	Homo sapiens (human)
myelin sheath	Carbonic anhydrase 2	Homo sapiens (human)
apical part of cell	Carbonic anhydrase 2	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 2	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 2	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 2	Homo sapiens (human)
apical part of cell	Carbonic anhydrase 2	Homo sapiens (human)
cytosol	Carbonic anhydrase 3	Homo sapiens (human)
cytosol	Carbonic anhydrase 3	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 3	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
rough endoplasmic reticulum	Carbonic anhydrase 4	Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment	Carbonic anhydrase 4	Homo sapiens (human)
Golgi apparatus	Carbonic anhydrase 4	Homo sapiens (human)
trans-Golgi network	Carbonic anhydrase 4	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
external side of plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
cell surface	Carbonic anhydrase 4	Homo sapiens (human)
membrane	Carbonic anhydrase 4	Homo sapiens (human)
apical plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
transport vesicle membrane	Carbonic anhydrase 4	Homo sapiens (human)
secretory granule membrane	Carbonic anhydrase 4	Homo sapiens (human)
brush border membrane	Carbonic anhydrase 4	Homo sapiens (human)
perinuclear region of cytoplasm	Carbonic anhydrase 4	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 4	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
extracellular region	Carbonic anhydrase 6	Homo sapiens (human)
extracellular space	Carbonic anhydrase 6	Homo sapiens (human)
cytosol	Carbonic anhydrase 6	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 6	Homo sapiens (human)
extracellular space	Carbonic anhydrase 6	Homo sapiens (human)
mitochondrial matrix	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
mitochondrion	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
mitochondrion	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
cytosol	Carbonic anhydrase 7	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 7	Homo sapiens (human)
nucleolus	Carbonic anhydrase 9	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 9	Homo sapiens (human)
membrane	Carbonic anhydrase 9	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 9	Homo sapiens (human)
microvillus membrane	Carbonic anhydrase 9	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 9	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 14	Homo sapiens (human)
membrane	Carbonic anhydrase 14	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 14	Homo sapiens (human)
apical plasma membrane	Carbonic anhydrase 14	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 14	Homo sapiens (human)
mitochondrion	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
mitochondrial matrix	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
mitochondrion	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1345957	Human carbonic anhydrase 14 (4.2.1.1 Carbonate dehydratases)	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID1345957	Human carbonic anhydrase 14 (4.2.1.1 Carbonate dehydratases)	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1346202	Human carbonic anhydrase 7 (4.2.1.1 Carbonate dehydratases)	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID1346202	Human carbonic anhydrase 7 (4.2.1.1 Carbonate dehydratases)	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1346003	Human carbonic anhydrase 4 (4.2.1.1 Carbonate dehydratases)	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID1346003	Human carbonic anhydrase 4 (4.2.1.1 Carbonate dehydratases)	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1346210	Human carbonic anhydrase 12 (4.2.1.1 Carbonate dehydratases)	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID1346210	Human carbonic anhydrase 12 (4.2.1.1 Carbonate dehydratases)	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID328975	Inhibition of human full length carbonic anhydrase 2	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID367612	Inhibition of human recombinant full length CA5A by stopped-flow CO2 hydration method	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367612	Inhibition of human recombinant full length CA5A by stopped-flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID367610	Inhibition of human recombinant full length CA3 by stopped-flow CO2 hydration method	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367610	Inhibition of human recombinant full length CA3 by stopped-flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID367609	Inhibition of human recombinant full length CA2 by stopped-flow CO2 hydration method	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367609	Inhibition of human recombinant full length CA2 by stopped-flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID328980	Inhibition of human full length carbonic anhydrase 6	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID411538	Inhibition of human recombinant CA14 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411538	Inhibition of human recombinant CA14 by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID409956	Inhibition of mouse brain MAOB	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID496832	Antimicrobial activity against Trypanosoma brucei rhodesiense	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID496830	Antimicrobial activity against Leishmania major	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID411532	Inhibition of human recombinant CA5B by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411532	Inhibition of human recombinant CA5B by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID411530	Inhibition of human recombinant CA4 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411530	Inhibition of human recombinant CA4 by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID19424	Partition coefficient (logD7.4)	2001	Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15	ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID496824	Antimicrobial activity against Toxoplasma gondii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID106805	Compound was tested for the inhibition of malate dehydrogenase (MDH) at 200 uM	2003	Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21	Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID411527	Inhibition of human recombinant CA1 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411527	Inhibition of human recombinant CA1 by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID367617	Inhibition of human recombinant CA12 catalytic domain by stopped-flow CO2 hydration method	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367617	Inhibition of human recombinant CA12 catalytic domain by stopped-flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID496818	Antimicrobial activity against Trypanosoma brucei brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID411535	Inhibition of human recombinant CA9 catalytic domain by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411535	Inhibition of human recombinant CA9 catalytic domain by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID411537	Inhibition of mouse recombinant CA13 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411537	Inhibition of mouse recombinant CA13 by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID411534	Inhibition of human recombinant CA7 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411534	Inhibition of human recombinant CA7 by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID27167	Delta logD (logD6.5 - logD7.4)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID496825	Antimicrobial activity against Leishmania mexicana	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496828	Antimicrobial activity against Leishmania donovani	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID411533	Inhibition of human recombinant CA6 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411533	Inhibition of human recombinant CA6 by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID328974	Inhibition of human full length carbonic anhydrase 1	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID496821	Antimicrobial activity against Leishmania	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID367619	Inhibition of human recombinant full length CA14 by stopped-flow CO2 hydration method	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367619	Inhibition of human recombinant full length CA14 by stopped-flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID496826	Antimicrobial activity against Entamoeba histolytica	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID367618	Inhibition of mouse recombinant full length CA13 by stopped-flow CO2 hydration method	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367618	Inhibition of mouse recombinant full length CA13 by stopped-flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID328982	Inhibition of human catalytic domain carbonic anhydrase 9	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID496817	Antimicrobial activity against Trypanosoma cruzi	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID367615	Inhibition of human recombinant full length CA7 by stopped-flow CO2 hydration method	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367615	Inhibition of human recombinant full length CA7 by stopped-flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID496829	Antimicrobial activity against Leishmania infantum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID411536	Inhibition of human recombinant CA12 catalytic domain by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411536	Inhibition of human recombinant CA12 catalytic domain by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID29363	Dissociation constant (pKa)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID496819	Antimicrobial activity against Plasmodium falciparum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID496831	Antimicrobial activity against Cryptosporidium parvum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID29813	Oral bioavailability in human	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID328984	Inhibition of mouse full length carbonic anhydrase 13	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID411531	Inhibition of human recombinant CA5A by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411531	Inhibition of human recombinant CA5A by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID496827	Antimicrobial activity against Leishmania amazonensis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID28681	Partition coefficient (logD6.5)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID52790	Inhibition of chymotrypsin at 250 uM	2003	Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21	Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID43581	Inhibition of beta-lactamase at 100 uM	2003	Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21	Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID367608	Inhibition of human recombinant full length CA1 by stopped-flow CO2 hydration method	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367608	Inhibition of human recombinant full length CA1 by stopped-flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID496823	Antimicrobial activity against Trichomonas vaginalis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496820	Antimicrobial activity against Trypanosoma brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID361985	Lipophilicity, log D of compound at pH 7.4 by microfluidic liquid-liquid extraction method	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Determination of log D via automated microfluidic liquid-liquid extraction.
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID328978	Inhibition of human full length carbonic anhydrase 5A	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID328985	Inhibition of human full length carbonic anhydrase 14	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID367616	Inhibition of human recombinant CA9 catalytic domain by stopped-flow CO2 hydration method	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367616	Inhibition of human recombinant CA9 catalytic domain by stopped-flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID367614	Inhibition of human recombinant full length CA6 by stopped-flow CO2 hydration method	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367614	Inhibition of human recombinant full length CA6 by stopped-flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID367613	Inhibition of human recombinant full length CA5B by stopped-flow CO2 hydration method	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367613	Inhibition of human recombinant full length CA5B by stopped-flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID411528	Inhibition of human recombinant CA2 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411528	Inhibition of human recombinant CA2 by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID497005	Antimicrobial activity against Pneumocystis carinii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID361986	Lipophilicity, log D of compound at pH 7.4 by shake flask method	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Determination of log D via automated microfluidic liquid-liquid extraction.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID367611	Inhibition of human recombinant full length CA4 by stopped-flow CO2 hydration method	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367611	Inhibition of human recombinant full length CA4 by stopped-flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID328979	Inhibition of human full length carbonic anhydrase 5B	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID328981	Inhibition of human full length carbonic anhydrase 7	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID328977	Inhibition of human full length carbonic anhydrase 4	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID328983	Inhibition of human catalytic domain carbonic anhydrase 12	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID411529	Inhibition of human recombinant CA3 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411529	Inhibition of human recombinant CA3 by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID328976	Inhibition of human full length carbonic anhydrase 3	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1798598	CA Inhibition Assay from Article 10.1016/j.bmcl.2008.03.051: \\Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.\\	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1803141	CA Inhibition Assay from Article 10.3109/14756366.2011.638921: \\Carbonic anhydrases inhibitory effects of new benzenesulfonamides synthesized by using superacid chemistry.\\	2012	Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 27, Issue:6	Carbonic anhydrases inhibitory effects of new benzenesulfonamides synthesized by using superacid chemistry.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1224864	HCS microscopy assay (F508del-CFTR)	2016	PloS one, , Volume: 11, Issue:10	Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	917 (59.70)	18.7374
1990's	139 (9.05)	18.2507
2000's	168 (10.94)	29.6817
2010's	214 (13.93)	24.3611
2020's	98 (6.38)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	486 (29.72%)	5.53%
Reviews	100 (6.12%)	6.00%
Case Studies	79 (4.83%)	4.05%
Observational	7 (0.43%)	0.25%
Other	963 (58.90%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (82)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Study to Evaluate the Safety and Efficacy of Chlorthalidone in Combination With Amiloride as a Treatment for Elderly Patients With Arterial Hypertension [NCT01191450]	Phase 3	280 participants (Anticipated)	Interventional	2011-08-31	Recruiting
A Randomized, Open-label, Single Dose, Replicate Crossover Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers [NCT03662620]	Phase 1	67 participants (Actual)	Interventional	2018-10-05	Completed
The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide. A Randomized Controled Trial [NCT04393493]	Phase 2	80 participants (Actual)	Interventional	2017-07-01	Completed
An Observational Study to Evaluate the Efficacy and Safety of Amosartan Plus Tablet in Uncontrolled Essential Hypertension Patients [NCT05462535]		4,785 participants (Actual)	Observational	2018-02-26	Completed
Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect. Comparison Between an ATII Receptor Antagonist and a Diuretic. [NCT03560804]		60 participants (Actual)	Interventional	2014-11-10	Completed
A 12-week, Multi-Center, Randomized Double-Blind, Active Control Parallel Group Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertens [NCT01368536]	Phase 4	975 participants (Actual)	Interventional	2011-05-31	Terminated(stopped due to Based on results from an ALTITUDE study interim analysis, testing aliskiren concomitantly with an ACE inhibitor or ARB, in diabetics with renal impairment)
Evaluation of the Efficacy and Safety of S-amlodipine+Chlorthalidone Combination Therapy and S-amlodipine+Telmisartan Combination Therapy in Hypertensive Patients Inadequately Controlled With Calcium Channel Blocker Monotherapy [NCT03226340]	Phase 4	170 participants (Anticipated)	Interventional	2015-12-02	Recruiting
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Candesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control [NCT02521233]	Phase 3	0 participants (Actual)	Interventional	2016-11-30	Withdrawn(stopped due to Sponsor decision)
An Open-Label, Superiority, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination Versus Telmisartan, Amlodipine, and Hydrochlorothiazide in Elderly Patients With Essential [NCT06041529]	Phase 4	250 participants (Anticipated)	Interventional	2023-09-14	Not yet recruiting
Evaluation of Platelet Effects of Chlorthalidone and Hydrochlorothiazide [NCT02100462]	Phase 4	30 participants (Anticipated)	Interventional	2014-03-31	Recruiting
The Management of Resistant Hypertension in Kidney Transplant Patients Using Chlorthalidone [NCT02030314]	Phase 4	0 participants (Actual)	Interventional	2013-07-31	Withdrawn(stopped due to The patient population changed. Unable to find patients that meet study criteria)
Efficacy of Chlorthalidone and Hydrochlorothiazide in Combination With Amiloride in Multiple Doses on Blood Pressure in Patients With Primary Hypertension: a Factorial Randomized Controlled Trial. [NCT03928145]	Phase 3	84 participants (Anticipated)	Interventional	2019-11-13	Recruiting
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Candesartan Cilexetil + Chlorthalidone (16mg + 12.5mg and 16mg + 25mg) Compared With HYZAAR® in Hypertension Control [NCT02521246]	Phase 3	0 participants (Actual)	Interventional	2016-11-30	Withdrawn(stopped due to Sponsor decision)
A Randomized,Open-label,Single Dose,Crossover Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Comparison to the Co-administration of Twynsta and Hygroton in Healthy Volunteers [NCT02496910]	Phase 1	180 participants (Anticipated)	Interventional	2015-06-30	Completed
A Phase 3, Open-Label, Randomized, Long-Term Comparison of the Safety and Tolerability of the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs. Olmesartan Medoxomil-Hydrochlorothiazide Fixed-Dose Combination in Subjects With Essential Hypertension [NCT00996281]	Phase 3	837 participants (Actual)	Interventional	2009-10-31	Completed
Night-time Use of Thiazide Diuretics for Improved Reduction in Stone Risk in Stone Formers With Elevated Urine Calcium [NCT02711670]		10 participants (Actual)	Interventional	2014-02-28	Completed
Comparison of Optimal Hypertension Regimens (Part of the Ancestry Informative Markers in Hypertension (AIMHY) Programme - AIMHY-INFORM) [NCT02847338]	Phase 4	1,320 participants (Anticipated)	Interventional	2016-11-30	Recruiting
A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD) [NCT02502981]	Phase 4	154 participants (Actual)	Interventional	2014-06-30	Active, not recruiting
Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity [NCT04519164]	Phase 4	80 participants (Anticipated)	Interventional	2020-12-01	Recruiting
An Open-label, Multiple-dose, Two-arm Clinical Study to Evaluate the Drug-drug Interaction and Safety of Telmisartan, Amlodipine and/or Chlorthalidone in Healthy Adult Volunteers [NCT02152969]	Phase 1	66 participants (Actual)	Interventional	2014-05-31	Completed
Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate [NCT02665117]		61 participants (Actual)	Interventional	2015-01-31	Completed
A Multicenter, Double-blind, Controlled, Randomized Trial to Evaluate the Association Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension [NCT05920005]	Phase 3	698 participants (Anticipated)	Interventional	2023-08-22	Recruiting
Investigating the Relevance of Skin Sodium and Salt Sensitivity of Blood Pressure in Determining the Response to Anti-Hypertensive Drugs (INTREPID) [NCT05976438]		60 participants (Anticipated)	Interventional	2023-08-31	Not yet recruiting
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension [NCT05593055]	Phase 4	75 participants (Anticipated)	Interventional	2023-08-25	Recruiting
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]		22,213 participants (Actual)	Observational	2020-01-19	Completed
Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus [NCT02644395]	Phase 3	49 participants (Actual)	Interventional	2013-01-18	Completed
Pilot Study to Assess Blockade of Calcium Channels and Sodium Chloride Cotransporters for Physiologic Abnormalities in Liver Transplant Associated Hypertension [NCT05275907]	Phase 4	0 participants (Actual)	Interventional	2022-07-12	Withdrawn(stopped due to Screened participants did not meet inclusion criteria prior to study completion date)
Prevention of Hypertension in Patients With Pre-hypertension: PREVER-prevention Study [NCT00970931]	Phase 3	730 participants (Actual)	Interventional	2010-07-31	Completed
A Comparison Between Diuretics and Angiotensin-receptor Blocker Agents in Patients With Stage I Hypertension: PREVER-treatment Study [NCT00971165]	Phase 3	655 participants (Actual)	Interventional	2010-07-31	Completed
Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial [NCT03923933]	Phase 2	34 participants (Actual)	Interventional	2019-06-18	Completed
Interventional Prospective Cohort Study, Multi-center With Nested Case-control Studies (Family-based and Non-family Based) on Individuals With Resistant Arterial Hypertension. [NCT01083017]		74 participants (Actual)	Observational	2011-04-30	Completed
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study of the TAK 491 Plus Chlorthalidone Fixed-Dose Combination Compared With TAK-491 and Hydrochlorothiazide Coadministration Therapy in Subjects With Moderate to Severe Essential Hypertension [NCT00818883]	Phase 3	609 participants (Actual)	Interventional	2009-02-28	Completed
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Benicar HCT® (Olmesartan Medoxomil-Hydrochlorothiazide) in Subjects With Moderate to Severe Essential Hypertension [NCT00846365]	Phase 3	1,085 participants (Actual)	Interventional	2009-03-31	Completed
A Phase 3, Double-Blind, Randomized, Factorial, Efficacy and Safety Study of TAK 491 Plus Chlorthalidone Fixed-Dose Combination in Participants With Moderate to Severe Hypertension [NCT00847626]	Phase 3	1,711 participants (Actual)	Interventional	2009-01-31	Completed
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 When Co-administered With Chlorthalidone in Subjects With Essential Hypertension [NCT00591773]	Phase 3	551 participants (Actual)	Interventional	2007-09-30	Completed
A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Safety and Efficacy of YH22162 in Subjects With Essential Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment [NCT02620163]	Phase 3	381 participants (Actual)	Interventional	2015-12-31	Completed
Treatment of Hypertension In Adults With ThiaZIDES: Pragmatic Trial Pilot Study [NCT02591628]		2,027 participants (Actual)	Interventional	2015-08-31	Completed
A One-Year Phase 3, Open-Label Study to Evaluate the Safety and Tolerability of TAK-491 in Subjects With Essential Hypertension [NCT00695955]	Phase 3	669 participants (Actual)	Interventional	2007-06-30	Completed
A Phase 3b, Double-Blind, Randomized, 12-Week Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Moderate to Severe Hypertension [NCT01033071]	Phase 3	1,071 participants (Actual)	Interventional	2010-01-31	Completed
An 8-Month Phase 3, Open-Label Study With a Blinded Reversal Phase to Evaluate the Safety and Tolerability of TAK-491 in Subjects With Essential Hypertension [NCT00696384]	Phase 3	418 participants (Actual)	Interventional	2007-06-30	Completed
Association of Diuretics With Change in Extracellular Volume, Natriuretic Peptides, Symptoms, and Cardiovascular Outcomes in CKD [NCT05171686]	Phase 4	46 participants (Anticipated)	Interventional	2023-02-01	Recruiting
Creating an Active Collaborative Network of Comparative Effectiveness Researchers: A Randomized Study of Initial Diuretic Therapy for Hypertension. [NCT01748123]	Phase 4	0 participants (Actual)	Interventional	2016-08-31	Withdrawn(stopped due to Slow enrollment)
[NCT00000514]	Phase 3	0 participants	Interventional	1984-06-30	Completed
[NCT00000522]	Phase 2	0 participants	Interventional	1985-08-31	Completed
[NCT00000525]	Phase 3	233 participants (Actual)	Interventional	1986-07-31	Completed
Pharmacological Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Anti-hypertensive Treatment [NCT00006294]		37,939 participants (Actual)	Observational	1999-09-30	Completed
[NCT00000499]	Phase 2	0 participants	Interventional	1980-09-30	Completed
Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment [NCT05411991]	Phase 4	104 participants (Anticipated)	Interventional	2022-06-12	Recruiting
Pharmacogenomic Evaluation of Antihypertensive Responses 2 [NCT01203852]	Phase 4	839 participants (Actual)	Interventional	2010-08-31	Completed
VA HYPERTENSION SCREENING AND TREATMENT PROGRAM (PILOT STUDY) [NCT00007592]		0 participants	Observational	1989-06-30	Completed
Effect of Antihypertensive Agents on Diastolic Function in Patients With Sleep Apnea: Protocol for a Randomized Controlled Trial [NCT02896621]	Phase 3	69 participants (Actual)	Interventional	2014-12-07	Completed
Efficacy and Safety of the Fixed-dose Combination of Valsartan Plus Chlorthalidone Vs Valsartan or Chlorthalidone Alone in the Treatment of Arterial Hypertension, Open-label, Controlled, Randomized and Multicenter Trial [NCT01850160]	Phase 3	124 participants (Actual)	Interventional	2013-04-30	Completed
A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605 [NCT02916602]	Phase 3	340 participants (Actual)	Interventional	2015-04-30	Completed
Safety and Efficacy of Chlorthalidone to Reduce Urinary Calcium Excretion in Adolescents/Yount Adult With Type 1 Diabetes [NCT03325114]	Phase 2	1 participants (Actual)	Interventional	2019-06-28	Terminated(stopped due to COVID restrictions prohibit further study activies)
A Randomized, Open-Label, Phase 3 Study to Compare Long-Term Safety and Tolerability of the TAK-491 and Chlorthalidone Fixed-Dose Combination Versus Olmesartan Medoxomil and Hydrochlorothiazide Fixed-Dose Combination in Hypertensive Subjects With Moderate [NCT01309828]	Phase 3	153 participants (Actual)	Interventional	2011-03-31	Completed
Action to Control Cardiovascular Risk in Diabetes (ACCORD) [NCT00000620]	Phase 3	10,251 participants (Actual)	Interventional	1999-09-30	Completed
A Phase I Clinical Trial to Evaluate the Pharmacokinetic Interactions and Safety Between Telmisartan and Chlorthalidone in Healthy Male Volunteers. [NCT01806363]	Phase 1	60 participants (Anticipated)	Interventional	2012-11-30	Completed
A Phase-3 Randomized, Double-Blind, Efficacy and Safety Study Evaluating the Fixed Dose Combinations of TAK-491 Plus Chlorthalidone (40/12.5 mg and 40/25 mg) in Subjects With Grades 2 or 3 Essential Hypertension, Who Do Not Achieve Target Blood Pressure F [NCT01456169]	Phase 3	507 participants (Actual)	Interventional	2011-10-31	Completed
Comparative Effectiveness of Ambulatory Blood Pressure Monitoring vs Usual Care for Diagnosing and Managing Hypertension: A Pilot Study [NCT02121041]		28 participants (Actual)	Interventional	2014-05-31	Completed
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control [NCT02493322]	Phase 3	261 participants (Anticipated)	Interventional	2023-04-30	Not yet recruiting
The Effect of Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function in Hypertensive Patients: A Pilot Study [NCT01822860]	Phase 4	0 participants (Actual)	Interventional	2013-03-31	Withdrawn(stopped due to Study subjects were not able to be recruited)
[NCT02841280]	Phase 2	160 participants (Actual)	Interventional	2016-07-31	Completed
[NCT00000513]	Phase 3	0 participants	Interventional	1984-04-30	Completed
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan Medoxomil + Chlorthalidone (40mg + 12.5mg and 40mg + 25mg) Compared With BENICAR HCT® in Hypertension Control [NCT02483936]	Phase 3	348 participants (Anticipated)	Interventional	2023-04-30	Not yet recruiting
The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial [NCT04330300]	Phase 4	2,414 participants (Anticipated)	Interventional	2020-04-30	Suspended(stopped due to Challenges with funding and very low incidence of COVID-19 at Irish study site)
The Effect of Antihypertensive Agents Over Sleep Apnea: a Randomized Controlled Trial [NCT01896661]	Phase 3	53 participants (Actual)	Interventional	2014-12-31	Completed
CSP #597 - Diuretic Comparison Project [NCT02185417]	Phase 3	13,523 participants (Actual)	Interventional	2016-06-15	Completed
A Randomized, Open-label, 4-way Crossover Single Dose Clinical Trial to Investigate the Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405 When Administered Alone and in Combination in Healthy Male Volunteers [NCT02387554]	Phase 1	33 participants (Actual)	Interventional	2014-08-31	Completed
Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers. [NCT04757532]	Phase 1	9 participants (Actual)	Interventional	2020-12-03	Completed
Neural Mechanisms of Thiazide-induced Insulin Resistance [NCT00353652]	Phase 4	166 participants (Actual)	Interventional	2005-01-31	Completed
[NCT00000542]	Phase 3	0 participants	Interventional	1993-08-31	Completed
[NCT02357004]		0 participants (Actual)	Interventional	2015-02-28	Withdrawn(stopped due to Change in priority of interventional protocols)
Confirmatory Study of the Efficacy and Safety of the Combination of Losartan / Chlorthalidone vs Losartan / Hydrochlorothiazide in the Treatment of Patients With Essential Arterial Hypertension [NCT04927299]	Phase 3	190 participants (Anticipated)	Interventional	2022-06-30	Recruiting
Hypertension in Young Adults Trial [NCT05370599]	Phase 2	120 participants (Anticipated)	Interventional	2022-04-15	Recruiting
Spironolactone in Chronic Kidney Disease Enabled by Chlorthalidone: A Pilot Randomized Control Trial [NCT05222191]	Phase 2	24 participants (Anticipated)	Interventional	2022-02-01	Recruiting
Diuretic Use in Hemodialysis Patients With Residual Renal Function: a Proof of Concept Study [NCT05915286]	Phase 4	34 participants (Anticipated)	Interventional	2023-05-29	Recruiting
No Pharmacokinetic Interaction Between Chlorthalidone and Losartan, in Healthy Volunteers Under Fasting Conditions, Administered in Fixed Combination Against Individual Components Administered Jointly and Separately [NCT05090449]	Phase 1	36 participants (Actual)	Interventional	2019-05-01	Completed
A Prospective, Multicentre, Randomized, Open Label, Evaluator-Blind, Phase IV Study to Evaluate the Effect on Improvement of Left Ventricular Hypertrophy by the Control of Blood Pressure in Hypertension Patients With Aortic Valve Disease [NCT03666351]	Phase 4	128 participants (Actual)	Interventional	2018-10-18	Completed
Randomized, Double-blind, Crossover Trial Assessing the Efficacy of Indapamide and Chlorthalidone Compared to Hydrochlorothiazide for the Reduction of Urine Supersaturation for Kidney Stone Prevention [NCT06111885]	Phase 2	99 participants (Anticipated)	Interventional	2024-04-30	Not yet recruiting
Uric Acid and Hypertension in African Americans [NCT00241839]	Phase 3	150 participants (Actual)	Interventional	2005-08-31	Completed
[NCT01750294]	Phase 4	14 participants (Actual)	Interventional	2012-08-31	Completed
Tissue Sodium in Pre-hypertensive Patients [NCT02236520]	Phase 2	71 participants (Actual)	Interventional	2014-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00000620 (6) [back to overview]	First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.
NCT00000620 (6) [back to overview]	Death From Any Cause in the Glycemia Trial.
NCT00000620 (6) [back to overview]	First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]	First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.
NCT00000620 (6) [back to overview]	Stroke in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]	First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.
NCT00241839 (4) [back to overview]	Change in Overall Mean BP From Those Obtained by 24 Hour Ambulatory Blood Pressure Measurements (ABPM) 8-10 Weeks Minus Baseline.
NCT00241839 (4) [back to overview]	Change in Systolic Blood Pressure by Cuff After 8-10 Weeks Minus Baseline
NCT00241839 (4) [back to overview]	Change in Diastolic Blood Pressure by Cuff 8-10 Weeks Minus Baseline
NCT00241839 (4) [back to overview]	Change in Uric Acid (UA) Levels: Baseline Less End of Treatment
NCT00353652 (5) [back to overview]	HOMA-IR
NCT00353652 (5) [back to overview]	Sympathetic Nerve Activity
NCT00353652 (5) [back to overview]	Sympathetic Baroreflex Sensitivity
NCT00353652 (5) [back to overview]	Insulin
NCT00353652 (5) [back to overview]	24-hour Ambulatory Systolic Blood Pressure
NCT00591773 (15) [back to overview]	Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591773 (15) [back to overview]	Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure.
NCT00591773 (15) [back to overview]	Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg
NCT00591773 (15) [back to overview]	Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.
NCT00591773 (15) [back to overview]	Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591773 (15) [back to overview]	Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591773 (15) [back to overview]	Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591773 (15) [back to overview]	Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response.
NCT00591773 (15) [back to overview]	Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg
NCT00591773 (15) [back to overview]	Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591773 (15) [back to overview]	Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591773 (15) [back to overview]	Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591773 (15) [back to overview]	Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591773 (15) [back to overview]	Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591773 (15) [back to overview]	Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00695955 (6) [back to overview]	Number of Participants Reporting One or More Treatment-emergent Adverse Events From Day 1 Through End of the Study - Cohort 2.
NCT00695955 (6) [back to overview]	Number of Participants Reporting One or More Treatment-emergent Adverse Events From Day 1 Through End of the Study - Cohort 1.
NCT00695955 (6) [back to overview]	Change From Baseline in Sitting Clinic Systolic Blood Pressure - Cohort 2
NCT00695955 (6) [back to overview]	Change From Baseline in Sitting Clinic Systolic Blood Pressure - Cohort 1.
NCT00695955 (6) [back to overview]	Change From Baseline in Sitting Clinic Diastolic Blood Pressure - Cohort 1.
NCT00695955 (6) [back to overview]	Change From Baseline in Sitting Clinic Diastolic Blood Pressure - Cohort 2.
NCT00696384 (6) [back to overview]	Change From Double-blind Baseline (Week 26) in Sitting Clinic Diastolic Blood Pressure to Week 32
NCT00696384 (6) [back to overview]	Number of Participants With Adverse Events in the Double-Blind Baseline Phase
NCT00696384 (6) [back to overview]	Number of Participants With Adverse Events During the Open-Label Phase
NCT00696384 (6) [back to overview]	Change From Open Label Baseline (Week 0) in Sitting Clinic Systolic Blood Pressure to Week 26
NCT00696384 (6) [back to overview]	Change From Open Label Baseline (Week 0) in Sitting Clinic Diastolic Blood Pressure to Week 26
NCT00696384 (6) [back to overview]	Change From Double-blind Baseline (Week 26) in Sitting Clinic Systolic Blood Pressure to Week 32
NCT00818883 (15) [back to overview]	Percentage of Participants Who Reached Their Trough, Sitting, Clinic Systolic and Diastolic Blood Pressure Targets, Defined as <140/90 mm Hg Without Diabetes or Chronic Kidney Disease or <130/80 mm Hg With Diabetes or Chronic Kidney Disease
NCT00818883 (15) [back to overview]	Percentage of Participants Who Reached Their Trough, Sitting, Clinic Systolic Blood Pressure Targets, Defined as <140 mm Hg for Participants Without Diabetes or Chronic Kidney Disease or <130 mm Hg for Participants With Diabetes or Chronic Kidney Disease
NCT00818883 (15) [back to overview]	Change From Baseline in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing as Measured by Ambulatory Blood Pressure Monitoring.
NCT00818883 (15) [back to overview]	Change From Baseline in 24-hour Mean Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.
NCT00818883 (15) [back to overview]	Change From Baseline in 24-hour Mean Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.
NCT00818883 (15) [back to overview]	Change From Baseline in Mean Trough Diastolic Blood Pressure (22 to 24 Hours After Dosing) as Measured by Ambulatory Blood Pressure Monitoring.
NCT00818883 (15) [back to overview]	Change From Baseline in Mean Trough Systolic Blood Pressure (22 to 24 Hours After Dosing) as Measured by Ambulatory Blood Pressure Monitoring.
NCT00818883 (15) [back to overview]	Change From Baseline in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.
NCT00818883 (15) [back to overview]	Change From Baseline in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.
NCT00818883 (15) [back to overview]	Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.
NCT00818883 (15) [back to overview]	Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.
NCT00818883 (15) [back to overview]	Change From Baseline in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing as Measured by Ambulatory Blood Pressure Monitoring
NCT00818883 (15) [back to overview]	Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure
NCT00818883 (15) [back to overview]	Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure
NCT00818883 (15) [back to overview]	Percentage of Participants Who Reached Their Trough, Sitting, Clinic Diastolic Blood Pressure Target, Defined as <90 mm Hg for Participants Without Diabetes or Chronic Kidney Disease or <80 mm Hg for Participants With Diabetes or Chronic Kidney Disease.
NCT00846365 (16) [back to overview]	Change From Baseline in Trough Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure.
NCT00846365 (16) [back to overview]	Change From Baseline in 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Change From Baseline in Daytime Mean (6am to 10pm) Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Change From Baseline in Nighttime Mean (12am to 6am) Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Change From Baseline in Nighttime Mean (12am to 6am) Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
NCT00846365 (16) [back to overview]	Change From Baseline in Trough Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Change From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure
NCT00846365 (16) [back to overview]	Change From Baseline in 24-hour Mean Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as Defined as <90 mm Hg for Participants Without Diabetes or CKD or <80 mm Hg for Participants With Diabetes or CKD
NCT00846365 (16) [back to overview]	Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as <140 mm Hg for Participants Without Diabetes or CKD or <130 mm Hg for Participants With Diabetes or CKD
NCT00846365 (16) [back to overview]	Change From Baseline in 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Change From Baseline to Week 4 in Trough, Sitting, Clinic Systolic Blood Pressure.
NCT00846365 (16) [back to overview]	Change From Baseline in Daytime Mean (6am to 10pm) Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Percentage of Participants Who Achieve a Clinic Diastolic AND Systolic Blood Pressure Response, Defined as <140/90 mm Hg for Participants Without Diabetes or Chronic Kidney Disease (CKD) or <130/80 mm Hg for Participants With Diabetes or CKD
NCT00847626 (18) [back to overview]	Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.
NCT00847626 (18) [back to overview]	Change From Baseline to Week 8 in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring.
NCT00847626 (18) [back to overview]	Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.
NCT00847626 (18) [back to overview]	Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.
NCT00847626 (18) [back to overview]	Change From Baseline to Week 8 in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring.
NCT00847626 (18) [back to overview]	Change From Baseline to Week 8 in the Mean Trough Diastolic Blood Pressure (22 to 24 Hours After Dosing), as Measured by Ambulatory Blood Pressure Monitoring.
NCT00847626 (18) [back to overview]	Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pairwise Analysis)
NCT00847626 (18) [back to overview]	Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pooled Analysis)
NCT00847626 (18) [back to overview]	Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure
NCT00847626 (18) [back to overview]	Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pairwise Analysis)
NCT00847626 (18) [back to overview]	Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pooled Analysis)
NCT00847626 (18) [back to overview]	Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response at Week 8, Defined as Clinic Diastolic Blood Pressure <90 mm Hg and/or a Reduction of ≥10 mm Hg From Baseline.
NCT00847626 (18) [back to overview]	Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response at Week 8, as Defined by Clinic Systolic Blood Pressure <140 mm Hg and/or a Reduction of ≥20 mm Hg From Baseline.
NCT00847626 (18) [back to overview]	Percentage of Participants Who Achieve Both a Clinic Systolic and Diastolic Blood Pressure Response at Week 8.
NCT00847626 (18) [back to overview]	Change From Baseline to Week 8 in Trough, Sitting, Clinic Diastolic Blood Pressure
NCT00847626 (18) [back to overview]	Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.
NCT00847626 (18) [back to overview]	Change From Baseline to Week 8 in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
NCT00847626 (18) [back to overview]	Change From Baseline to Week 8 in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
NCT00996281 (2) [back to overview]	Percentage of Participants With Serum Creatinine Elevations Greater Than 50% From Baseline and Greater Than the Upper Limit of Normal (ULN)
NCT00996281 (2) [back to overview]	Percentage of Participants With at Least 1 Adverse Event
NCT01033071 (18) [back to overview]	Change From Baseline in the Mean Systolic Blood Pressure During Each Hour of the 24-hour Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure.
NCT01033071 (18) [back to overview]	Percent of Participants Who Reached Target Clinic Systolic Blood Pressure of <140 mm Hg and/or Reduction of ≥20 mm Hg From Baseline and Target Clinic Diastolic Blood Pressure of <90 mm Hg and/or Reduction of ≥10 mm Hg From Baseline.
NCT01033071 (18) [back to overview]	Change From Baseline in 24-hour Mean Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure.
NCT01033071 (18) [back to overview]	Percentage of Participants Who Reached Target Clinic Systolic Blood Pressure of <140 mm Hg and/or Reduction of ≥20 mm Hg From Baseline.
NCT01033071 (18) [back to overview]	Change From Baseline in 24-hour Mean Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in Mean Trough Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in Mean Trough Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure.
NCT01033071 (18) [back to overview]	Change From Baseline in the Mean Diastolic Blood Pressure During Each Hour of the 24-hour Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Percentage of Participants Who Reached Target Clinic Diastolic Blood Pressure of <90 mm Hg and/or Reduction of ≥10 mm Hg From Baseline.
NCT01203852 (2) [back to overview]	Adverse Metabolic Effects
NCT01203852 (2) [back to overview]	Change in Blood Pressure From Baseline to Treatment
NCT01309828 (4) [back to overview]	Percentage of Participants at Final Visit Who Achieve Target Systolic Blood Pressure <130 mm Hg
NCT01309828 (4) [back to overview]	Percentage of Participants at Final Visit Who Achieved Both a Clinic Systolic and Diastolic Blood Pressure Response
NCT01309828 (4) [back to overview]	Percentage of Participants at Final Visit Who Achieved Target Diastolic Blood Pressure <80 mm Hg
NCT01309828 (4) [back to overview]	Number of Participants With at Least 1 Adverse Event (AE)
NCT01368536 (1) [back to overview]	Number of Patients With Adverse Events, Serious Adverse Events and Death to Assess Safety and Tolerability of Treatment With Valturna and Chlorthalidone or Valturna and Amlodipine Versus Valturna Alone
NCT01456169 (15) [back to overview]	Change From Baseline to Week 8 in the Mean Nighttime Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
NCT01456169 (15) [back to overview]	Change From Baseline to Week 8 in the Mean Nighttime Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
NCT01456169 (15) [back to overview]	Change From Baseline to Week 8 in Trough Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring
NCT01456169 (15) [back to overview]	Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring
NCT01456169 (15) [back to overview]	Change From Baseline to Week 8 in Trough, Sitting, Clinic Diastolic Blood Pressure
NCT01456169 (15) [back to overview]	Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure
NCT01456169 (15) [back to overview]	Change From Baseline to Week 8 in the Mean Systolic Blood Pressure 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring
NCT01456169 (15) [back to overview]	Percentage of Participants Who Achieve a Target Clinic Diastolic Blood Pressure at Week 8
NCT01456169 (15) [back to overview]	Percentage of Participants Who Achieve a Target Clinic Systolic Blood Pressure at Week 8
NCT01456169 (15) [back to overview]	Percentage of Participants Who Achieve Both Clinic Systolic and Diastolic Blood Pressure Targets at Week 8
NCT01456169 (15) [back to overview]	Change From Baseline to Week 8 in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
NCT01456169 (15) [back to overview]	Change From Baseline to Week 8 in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
NCT01456169 (15) [back to overview]	Change From Baseline to Week 8 in the Mean Daytime Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
NCT01456169 (15) [back to overview]	Change From Baseline to Week 8 in the Mean Daytime Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
NCT01456169 (15) [back to overview]	Change From Baseline to Week 8 in the Mean Diastolic Blood Pressure 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring
NCT01750294 (1) [back to overview]	Change of Systolic Ambulatory Blood Pressure From Baseline to 12 Weeks
NCT02121041 (1) [back to overview]	24 Hour Blood Pressure Average at the End of 4 Month Participation.
NCT02236520 (1) [back to overview]	Change in Tissue Sodium Concentration Measured Using Sodium Magnetic Resonance Imaging (NaMRI)
NCT02387554 (1) [back to overview]	AUClast
NCT02665117 (4) [back to overview]	Change in Fasting Plasma Glucose From Week 4 to Week 16
NCT02665117 (4) [back to overview]	Chang in Hepatic Fat Measured at Baseline and Week 16
NCT02665117 (4) [back to overview]	Change in Muscle Magnesium Content Measured at Baseline and Week 16
NCT02665117 (4) [back to overview]	Change in FGF23 From Week 4 to Week 16
NCT02841280 (5) [back to overview]	Change From Baseline to 12 Weeks in Systolic Ambulatory Blood Pressure in the Chlorthalidone Group Compared to Placebo.
NCT02841280 (5) [back to overview]	Change From Baseline at Each 4 Week Visit in Body Volume in the Chlorthalidone Group Compared to Placebo. No Adjustments Will be Made for Multiple Comparisons.
NCT02841280 (5) [back to overview]	Change From Baseline at Each 4 Week Visit in Log of Aldosterone and Log of Renin in the Chlorthalidone Group Compared to Placebo. No Adjustments Will be Made for Multiple Comparisons.
NCT02841280 (5) [back to overview]	Change From Baseline at Each 4 Week Visit in Log of N-terminal Pro B-type Natriuretic Peptide (NTproBNP) in the Chlorthalidone Group Compared to Placebo. No Adjustments Will be Made for Multiple Comparisons.
NCT02841280 (5) [back to overview]	Changes in Albuminuria From Baseline at Each 4 Week Visit in the Log Transformed Albumin/Creatinine Ratio in the Chlorthalidone Group Compared to Placebo
NCT03923933 (7) [back to overview]	Change in Total Body Water
NCT03923933 (7) [back to overview]	Change in the Fractional Excretion of Sodium
NCT03923933 (7) [back to overview]	Change in Systolic Blood Pressure
NCT03923933 (7) [back to overview]	Change in Mean Arterial Pressure
NCT03923933 (7) [back to overview]	Change in Extracellular Water / Total Body Water Ratio
NCT03923933 (7) [back to overview]	Change in Diastolic Blood Pressure
NCT03923933 (7) [back to overview]	Change in Extracellular Water
NCT04393493 (24) [back to overview]	Change in Serum Calcium Levels Measured at Day One of Intervention From Serum Calcium Levels Measured at 96 Hrs After Intervention Started.
NCT04393493 (24) [back to overview]	An Elevation of at Least 0.3 mg/dl of Serum Creatinine From Day One of Intervention Compared With Serum Creatinine at 96hrs After Intervention Started
NCT04393493 (24) [back to overview]	Number of Patients That Achieved >30% Reduction in Brain Natriuretic Compared With Baseline Levels
NCT04393493 (24) [back to overview]	Change in Serum Bicarbonate Levels Measured at Day One of Intervention From Serum Bicarbonate Levels Measured at 96 Hrs After Intervention Started.
NCT04393493 (24) [back to overview]	Change in 24 Hour Urine Output at 96 Hours After Intervention Started From 24 Hour Urine Output One Day Before Intervention Initiation)
NCT04393493 (24) [back to overview]	Number of Patients With Dyspnea Improvement as Referred by the Patient or Reduction in Supplementary Oxygen Requirements at 96 Hours After Intervention Started
NCT04393493 (24) [back to overview]	Number of Patients With Dyspnea Improvement as Referred by the Patient or Reduction in Supplementary Oxygen Requirements Before Day 3 of Intervention
NCT04393493 (24) [back to overview]	Change in Serum Brain Natriuretic Peptide Levels at Baseline From Serum Brain Natriuretic Peptide Levels at 96 Hours After Intervention Started
NCT04393493 (24) [back to overview]	Number of Patients Whose Interventions Were Stopped Because Clinical Improvement Was Achieved Before 96 Hours as Assessed by de Clinical Judgement of the Medical Team in Charge.
NCT04393493 (24) [back to overview]	Number of Patients That Required Renal Replacement Therapy of Any Type During Intervention (4 Days).
NCT04393493 (24) [back to overview]	Number of Participants With Renal Function Recovery Defined as a Return to Individual Baseline Serum Creatinine Values
NCT04393493 (24) [back to overview]	Number of Days From the Beginning of the Intervention Until Patients Referred Dyspnea Improvement or a Reduction in Supplementary Oxygen Requirements Was Made.
NCT04393493 (24) [back to overview]	Mortality During Follow up Defined as Number of Dead Patients After Discharge
NCT04393493 (24) [back to overview]	In Hospital Mortality Defined as Number of Dead Patients From Day One of Intervention and Before Discharge
NCT04393493 (24) [back to overview]	Change in Serum Urea Levels Measured at Day One of Intervention From Serum Urea Levels Measured at 96 Hrs After Intervention Started.
NCT04393493 (24) [back to overview]	Change in Serum Sodium Levels Measured at Day One of Intervention From Serum Sodium Levels Measured at 96 Hrs After Intervention Started.
NCT04393493 (24) [back to overview]	Change in Serum Potassium Levels Measured at Day One of Intervention From Serum Potassium Levels Measured at 96 Hrs After Intervention Started.
NCT04393493 (24) [back to overview]	Change in Serum pH Value Measured at Day One of Intervention From Serum pH Value Measured at 96 Hrs After Intervention Started.
NCT04393493 (24) [back to overview]	Change in Serum Creatinine at Day One of Intervention From Serum Creatinine at 96 Hrs After Intervention Started
NCT04393493 (24) [back to overview]	Change in Serum Partial Pressure of Carbon Dioxide Measured at Day One of Intervention From Serum Partial Pressure of Carbon Dioxide Measured at 96 Hrs After Intervention Started.
NCT04393493 (24) [back to overview]	Change in Serum Magnesium Levels Measured at Day One of Intervention From Serum Magnesium Levels Measured at 96 Hrs After Intervention Started.
NCT04393493 (24) [back to overview]	Change in Serum Lactate Levels Measured at Day One of Intervention From Serum Lactate Levels Measured at 96 Hrs After Intervention Started.
NCT04393493 (24) [back to overview]	Change in Serum Copeptin Levels at Day One of Intervention From Serum Copeptin Levels Measured at 96 Hrs After Intervention Started.
NCT04393493 (24) [back to overview]	Change in Serum Chloride Levels Measured at Day One of Intervention From Serum Chloride Levels Measured at 96 Hrs After Intervention Started.

First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years

Intervention	participants (Number)
Lipid Trial: Fenofibrate	291
Lipid Trial: Placebo	310

Intervention	participants (Number)
Glycemia Trial: Intensive Control	391
Glycemia Trial: Standard Control	327

Intervention	mU/l*mmol/l (Median)
Study#1: Chlorthalidone (CTD), Titrated Dose	1.91
Study #1: Spironolactone (SP), Titrated Dose	1.33
Study# 2 Chlorthalidone (CTD), Fixed Dose	1.87
Study# 2 CTD Fixed Dose 25 mg/d Plus SP Fixed Dose	0.85
Study# 2 CTD Fixed Dose 25 mg/d Plus IR Fixed Dose	1.42

Intervention	% change from baseline per mmHg (Mean)
Study#1: Chlorthalidone (CTD), Titrated Dose	-9.1
Drug: Study #1: Spironolactone (SP), Titrated Dose	-15.2
Study# 2 Chlorthalidone (CTD), Fixed Dose	-12.9
Study# 2 CTD Fixed Dose 25 mg/d Plus SP Fixed Dose	-11.3
Study# 2 CTD Fixed Dose 25 mg/d Plus IR Fixed Dose	-12.0

Intervention	mU/liter (Median)
Study#1: Chlorthalidone (CTD), Titrated Dose	8.24
Study #1: Spironolactone (SP), Titrated Dose	7.6
Study# 2 CTD Fixed Dose 25 mg/d	7.6
Study# 2 CTD Fixed Dose 25 mg/d Plus SP Fixed Dose	4.87
Study# 2 CTD Fixed Dose 25 mg/d Plus IR Fixed Dose	6.8

Intervention	mmHg (Mean)
Study#1: Chlorthalidone (CTD), Titrated Dose	127.4
Study #1: Spironolactone (SP), Titrated Dose	128.6
Study# 2 Chlorthalidone (CTD), Fixed Dose	123.5
Study# 2 CTD Fixed Dose 25 mg/d Plus SP Fixed Dose	121.6
Study# 2 CTD Fixed Dose 25 mg/d Plus IR Fixed Dose	119.8

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	-33.02
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	-32.45
Chlorthalidone 25 mg QD	-15.50

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	-16.18
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	-15.98
Chlorthalidone 25 mg QD	-8.93

Intervention	percentage of participants (Number)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	92.7
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	90.3
Chlorthalidone 25 mg QD	78.1

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	-36.16
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	-34.44
Chlorthalidone 25 mg QD	-21.76

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	-18.82
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	-18.99
Chlorthalidone 25 mg QD	-7.79

Intervention	mm Hg (Mean)
A (Allopurinol)	-5.9
B (Placebo)	0.90

Intervention	mm Hg (Mean)
A (Allopurinol)	0.21
B (Placebo)	-0.95

Intervention	mm Hg (Mean)
A (Allopurinol)	3.44
B (Placebo)	-0.83

Intervention	mg/dl (Mean)
A (Allopurinol)	2.29
B (Placebo)	0.14

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	-32.53
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	-31.97
Chlorthalidone 25 mg QD	-15.73

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	-19.06
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	-19.20
Chlorthalidone 25 mg QD	-7.53

Intervention	percentage of participants (Number)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	84.9
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	80.7
Chlorthalidone 25 mg QD	58.4

Intervention	percentage of participants (Number)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	87.7
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	84.1
Chlorthalidone 25 mg QD	63.5

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	-30.73
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	-30.16
Chlorthalidone 25 mg QD	-16.69

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	-18.78
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	-19.04
Chlorthalidone 25 mg QD	-9.36

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	-29.52
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	-29.43
Chlorthalidone 25 mg QD	-16.59

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	-17.05
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	-17.06
Chlorthalidone 25 mg QD	-8.89

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	-31.72
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	-31.30
Chlorthalidone 25 mg QD	-15.85

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	-18.28
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	-18.49
Chlorthalidone 25 mg QD	-7.99

chlorthalidone

Description

Cross-References

Synonyms (201)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (3)

Pathways (1)

Protein Targets (25)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (61)

Molecular Functions (31)

Ceullar Components (34)

Bioassays (212)

Research

Studies (1,536)

Market Indicators

Research Demand Index: 113.54

Study Types

Clinical Trials (82)

Trial Overview

Trial Outcomes

First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.

Death From Any Cause in the Glycemia Trial.

First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.

First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.

Stroke in the Blood Pressure Trial.

First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.

Change in Overall Mean BP From Those Obtained by 24 Hour Ambulatory Blood Pressure Measurements (ABPM) 8-10 Weeks Minus Baseline.

Change in Systolic Blood Pressure by Cuff After 8-10 Weeks Minus Baseline

Change in Diastolic Blood Pressure by Cuff 8-10 Weeks Minus Baseline

Change in Uric Acid (UA) Levels: Baseline Less End of Treatment

HOMA-IR

Sympathetic Nerve Activity

Sympathetic Baroreflex Sensitivity

Insulin

24-hour Ambulatory Systolic Blood Pressure

Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure.

Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg

Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.

Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response.

Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg

Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Number of Participants Reporting One or More Treatment-emergent Adverse Events From Day 1 Through End of the Study - Cohort 2.

Number of Participants Reporting One or More Treatment-emergent Adverse Events From Day 1 Through End of the Study - Cohort 1.

Change From Baseline in Sitting Clinic Systolic Blood Pressure - Cohort 2

Change From Baseline in Sitting Clinic Systolic Blood Pressure - Cohort 1.

Change From Baseline in Sitting Clinic Diastolic Blood Pressure - Cohort 1.

Change From Baseline in Sitting Clinic Diastolic Blood Pressure - Cohort 2.

Change From Double-blind Baseline (Week 26) in Sitting Clinic Diastolic Blood Pressure to Week 32

Number of Participants With Adverse Events in the Double-Blind Baseline Phase

Number of Participants With Adverse Events During the Open-Label Phase

Change From Open Label Baseline (Week 0) in Sitting Clinic Systolic Blood Pressure to Week 26

Change From Open Label Baseline (Week 0) in Sitting Clinic Diastolic Blood Pressure to Week 26

Change From Double-blind Baseline (Week 26) in Sitting Clinic Systolic Blood Pressure to Week 32

Percentage of Participants Who Reached Their Trough, Sitting, Clinic Systolic and Diastolic Blood Pressure Targets, Defined as <140/90 mm Hg Without Diabetes or Chronic Kidney Disease or <130/80 mm Hg With Diabetes or Chronic Kidney Disease

Percentage of Participants Who Reached Their Trough, Sitting, Clinic Systolic Blood Pressure Targets, Defined as <140 mm Hg for Participants Without Diabetes or Chronic Kidney Disease or <130 mm Hg for Participants With Diabetes or Chronic Kidney Disease

Change From Baseline in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing as Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in 24-hour Mean Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in 24-hour Mean Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in Mean Trough Diastolic Blood Pressure (22 to 24 Hours After Dosing) as Measured by Ambulatory Blood Pressure Monitoring.

Intervention	participants (Number)
	Number of Participants	Percentage of Participants
Cohort 2	241	78.5

Intervention	participants (Number)
	Number of Participants	Percentage of Participants
Cohort 1	267	73.8

Intervention	mmHg (Mean)
	Week 4	Week 8	Week 12	Week 16	Week 26	Week 36	Week 46	Week 56	Final Visit
Cohort 2	-14.4	-17.5	-23.8	-26.2	-24.8	-22.5	-23.8	-24.2	-22.7

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil QD - Double Blind Reversal Phase	0.14
Placebo QD - Double Blind Reversal Phase	7.92

Intervention	participants (Number)
	Serious Adverse Events	Treatment Emergent Adverse Events
Azilsartan Medoxomil QD - Double Blind Reversal Phase	0	42
Placebo QD - Double Blind Reversal Phase	1	38

Intervention	participants (Number)
	Serious Adverse Events	Treatment Emergent Adverse Events
Azilsartan Medoxomil QD - Open Label Phase	8	226

Intervention	percentage of participants (Number)
	Week 2 (n=283; n=276)	Week 4 (n=292; n=289)	Week 6 (n=295; n=292)	Week 8 (n=295; n=292)	Week 10 (n=295; n=292)
Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD	24.6	45.3	45.9	59.2	62.3
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	27.2	58.6	64.1	72.5	71.5

Intervention	mmHg (Least Squares Mean)
	Week 6 (n=179; n=162)	Week 10 (n=227; n=230)
Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD	-11.1	-12.9
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-15.7	-16.0

Intervention	mmHg (Least Squares Mean)
	Week 6 (n=179, n=162)	Week 10 (n=227, n=230)
Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD	-19.9	-22.4
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-25.7	-26.6

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=223; n=227; n=219)	Week 8 (n=290; n=278; n=281)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-22.4	-24.9
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-23.6	-26.8
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-17.4	-19.6